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ABSTRACT 
Timothy Brandon Campbell 
 
IN VIVO HEMATOPOIETIC CELL ENGRAFTMENT IS MODULATED BY DPPIV/CD26 
INHIBITION AND RHEB2 OVEREXPRESSION 
 
Hematopoietic cell transplantation (HCT) is an important modality used to treat 
patients with hematologic diseases and malignancies. A better understanding of the 
biological processes controlling hematopoietic cell functions such as migration/homing, 
proliferation and self-renewal is required for improving HCT therapies. This study 
focused on the role of two biologically relevant proteins, dipeptidylpeptidase IV 
(DPPIV/CD26) and Ras homologue enriched in brain 2 (Rheb2), in modulating 
hematopoietic cell engraftment. The first goal of this study was to determine the role of 
the protein DPPIV/CD26 in modulating the engraftment of human umbilical cord blood 
(hUCB) CD34+ stem/progenitor cells using a NOD/SCID mouse xenograft model, and 
based upon previous work demonstrating a role for this enzyme in Stromal-Derived 
Factor-1/CXCL12 mediated migration and homing. Related to this first goal, 
pretreatment with an inhibitor of DPPIV/CD26 peptidase activity increased engraftment 
of hUCB CD34+ cells in vivo in recipient Non Obese Diabetic/Severe Combined 
Immunodeficiency (NOD/SCID) mice while not disturbing their differentiation potential 
following transplantation. These results support using DPPIV/CD26 inhibition as a 
strategy for enhancing the efficacy of cord blood transplantation. The second goal was to 
determine, by overexpression, the role of the Rheb2 in affecting the balance between 
proliferation and in vivo repopulating activity of mouse hematopoietic cells. Rheb2 is 
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known to activate the mammalian target of rapamycin (mTOR) pathway, a pathway 
important in hematopoiesis. Rheb2 overexpression increased the proliferation and 
mTOR signaling of two hematopoietic cell lines, 32D and BaF3, in response to delayed 
IL-3 addition. In primary mouse hematopoietic cells, Rheb2 overexpression enhanced 
the proliferation and expansion of hematopoietic progenitor cells (HPCs) and phenotypic 
hematopoietic stem cells (HSCs) in vitro. In addition, HPC survival was enhanced by 
Rheb2 overexpression. Using in vivo competitive repopulation assays, Rheb2 
overexpression transiently expanded immature HPC/HSC populations shortly after 
transplantation, but reduced the engraftment of total transduced cells. These findings 
support previous work showing that signaling proteins able to enhance the proliferative 
status of hematopoietic stem cells often cause exhaustion of self-renewal and 
repopulating ability. These studies of hematopoietic engraftment modulated by both of 
these molecules provide information which may be important to future work on HCT.     
 
 
 
                                                                            Hal E. Broxmeyer Ph.D., Chair 
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INTRODUCTION 
Hematopoiesis is a highly coordinated physiological process by which immature 
hematopoietic stem cells (HSCs) differentiate to form mature lineages of the blood, as 
well as undergo self-renewal to prevent exhaustion and depletion. Hematopoiesis has 
generally been thought to occur in a hierarchal manner in which HSCs differentiate to 
form immature hematopoietic progenitor cells (HPCs)(Bellantuono 2004), and undergo 
further expansion and differentiation to form mature HPCs (Bellantuono 2004). Mature 
HPCs can further expand and differentiate into each terminal lineage of the blood 
system, including all myeloid and lymphoid derivatives. Self-renewal potential, measured 
by the ability of the HSCs to long-term repopulate transplant recipients, is contained 
mainly within the immature HSC populations. Elucidating the mechanisms involved in 
controlling HSC repopulation and self-renewal has been a focus of hematopoietic 
research for many years with immense clinical implications. Before discussing ways in 
which this study has approached this issue, an overview of hematopoiesis and 
transplantation biology will be discussed. 
In the mouse system, HSCs are typically subclassified as long-term and short-term 
repopulating HSCs (LT-HSC and ST-HSC) (Bellantuono 2004; Morrison and Weissman 
1994; Christensen and Weissman 2001; Shizuru et al. 2005). ST-HSCs can repopulate a 
transplant recipient in a transient manner, unable to maintain stable long-term 
repopulation (Morrison and Weissman 1994; Shizuru et al. 2005; Christensen and 
Weissman 2001). LT-HSC by contrast, are responsible for long-term repopulation of 
transplant recipients which can last the entire life of the animal as well as repopulate 
secondary and tertiary recipients (Bellantuono 2004; Morrison and Weissman 1994; 
Christensen and Weissman 2001). Only the LT-HSCs, ST-HSCs and to a minor extent, 
the MPPs, contain multi-lineage repopulating ability. These populations are distinguished 
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based on phenotypic and functional characteristics. Both of these populations lack 
lineage antigens which identify mature B cells, T cells, neutrophils, macrophages, and 
erythrocytes as indicated by the Lin- designation and express cell-surface molecules 
including c-kit (stem cell factor receptor) and stem cell antigen -1 (Sca-1). The presence 
or absence of other cell-surface antigens such as Flk-2 and Thy1.1 can be used to 
further phenotypically distinguish these populations (Bellantuono 2004; Christensen and 
Weissman 2001). Other hematopoietic populations can be distinguished by surface 
markers and functional assays. These include the multi-potent progenitors (MPP) which 
are immediate downstream derivatives of the HSC cells and are able to differentiate to 
both myeloid and lymphoid lineages; however, they lack measurable self-renewal ability 
and cannot maintain long-term engraftment in a transplant recipient (Bellantuono 2004; 
Shizuru et al. 2005). These cells further differentiate to common myeloid and common 
lymphoid progenitors (CMPs and CLPs) which can differentiate to form all the cells of 
either the myeloid or lymphoid lineages but, for the most part, are restricted to either one 
of these two lineages and do not crossover (Shizuru et al. 2005; Akashi et al. 2000; 
Kondo et al. 1997). Finally, the CMPs and CLPs differentiate to more restricted, mature 
progenitors such as CFU-GM (granulocyte-macrophage progenitor), BFU-E (erythroid 
progenitor) and others. All of these progenitors have substantial ability to expand and 
differentiate towards their mature, daughter cell types, e.g. neutrophils or B cells, and 
lack self-renewal ability. With differentiation of these progenitors, the expression of 
lineage antigens increases. Techniques such as semi-solid colony-forming assays have 
been used as gold-standards for assessing progenitor cell number and behavior. A 
single progenitor cell can expand and differentiate to form a mature colony in semi-solid 
medium containing hematopoietic growth factors, which can be assessed based on cell 
morphology and other characteristics.  
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In the human system, the classification of subpopulations of stem and progenitor cells is 
less clear. CD34 positivity has long been accepted as a marker for stem cell populations 
in bone marrow and umbilical cord blood (UCB). It is recognized, however, that the 
CD34+ population is a heterogeneous mixture of immature stem and progenitor cells 
(Bhatia et al. 1997b; Link et al. 1996; Hao et al. 1995), and thus other markers have 
been proposed for use in isolating more defined populations. The absence of the 
myeloid cell-surface antigen, CD38, in combination with CD34 positivity can identify 
more immature HSC/HPCs. CD34+CD38- cells are more immature HSC/HPCs able to 
better repopulate immunodeficient NOD/SCID β2-microglobulin-null mice (Ishikawa et al. 
2003). Similar to mouse hematopoiesis, various combinations of cell-surface markers 
and functional assays are used in the human system to define subsets of progenitor 
cells, including CMPs and CLPs as well as others (Hoebeke et al. 2007; Chen et al. 
2007).  
Preservation and fidelity of self-renewal and differentiation in the HSC pool are essential 
for maintaining homeostatic conditions and preventing leukemic disease (Passegue and 
Weisman 2005; Lessard et al. 2004). The entire field of transplantation is dependent on 
this balance, and understanding how these events are regulated has immense clinical 
value. Over 50 years ago, researchers showed it was possible to protect mice and other 
animals from death after lethal radiation by transplanting bone marrow cells (Lorenz et 
al. 1951; Diaconescu and Storb 2005). These early experiments started the field of 
hematopoietic cell transplantation (HCT).  This therapy has been used to treat and/or 
cure a variety of diseases such as immunodeficiencies, aplastic anemia and 
myeloproliferative diseases including various leukemias (Diaconescu and Storb 2005). 
Advancements in this therapy have been tremendous in the last few decades. First, 
better ways of conditioning the recipient have resulted in better engraftment of stem cells 
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and better overall survival. Some of these ways include the use of cyclophosphamide 
(Cy) and its combination with fractionated doses of total body irradiation (TBI) or with 
other myelosuppressive agents such as busulfan (Thomas et al. 1982; Deeg et al. 1986; 
Santos et al. 1983). Second, better understanding of immunology, matching of HLA 
antigens, and better immunosuppressive therapies have led to less rejection and graft-
versus-host disease (GVHD), which has dramatically increased the post-transplant 
survival of patients as well as enabled allogeneic transplantation from unrelated bone 
marrow donors (Hansen et al. 1998; Diaconescu and Storb 2005). One of the most 
important ways in which HCT has been improved is the source of the transplantable 
donor cells. Two populations of transplantable HSC grafts have been used increasingly 
in the past 20 years. The first is composed of HSCs collected in the peripheral blood 
after mobilization out of the bone marrow (mobilized peripheral blood, MPB). The second 
is composed of HSCs collected from human umbilical cord blood (hUCB) after a baby’s 
birth.  
The most common mobilizing agent used clinically is granulocyte colony-stimulating 
factor (G-CSF) (Cashen et al. 2007; Pelus and Fukuda 2008; Nervi et al. 2006). G-CSF 
mobilized grafts are superior to BM grafts in post-transplantation time to stable 
engraftment and survival of the recipient, even though GVHD is similar between the two 
sources (Diaconescu and Storb 2005).  The mechanism of action of G-CSF in mobilizing 
HSCs is complicated and not fully understood. The interplay of adhesion molecules, 
matrix metalloproteases and other molecules are likely involved in this process (Lapidot 
and Petit 2002). Other mobilizing agents have been tested in both mouse and human 
systems.  Molecules such as the CXCR2 ligand Gro beta (Pelus and Fukuda 2006; 
Fukuda et al. 2007) and the CXCR4 antagonist AMD3100 (Broxmeyer et al. 2005; 
Broxmeyer et al. 2007) are effective at mobilizing HSCs. AMD3100 antagonizes the 
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stromal-derived factor 1/CXCL12 (SDF-1/CXCL12) chemokine, CXCR4 chemokine 
receptor interaction, and its use as a potent mobilizing agent illustrates the importance of 
this axis in hematopoietic stem cell movement between the bone marrow and peripheral 
tissues (Broxmeyer et al. 2005; Broxmeyer et al. 2007).  
In addition to mobilized peripheral blood, hUCB contains transplantable hematopoietic 
stem cells capable of restoring the blood system of myeloablated recipients (Broxmeyer 
2006; Gluckman et al. 1989). There are advantages of hUCB over other sources of 
HSCs, including less GVHD,  lower risk of virally-contaminated grafts and no risk to the 
donor (Broxmeyer 2006; Lewis 2002).  
The work advancements summarized thus far, better conditioning regimens, better HLA 
matching and using alternative sources such as MPB and hUCB, have improved HCT. 
There still remain significant roadblocks in the application of HCT for the treatment of 
many hematologic diseases. There are still many recipients who cannot get a fully 
matched donor graft for HCT, many of whom have to resort to using haploidentical grafts 
(Diaconescu and Storb 2005; Hurley et al. 2003), and this number is higher for minorities 
such as African Americans (Diaconescu and Storb 2005). In addition, there is still 
significant morbidity and to an extent mortality, resulting from HCT, mostly related to 
engraftment failures, delayed engraftment, GVHD or issues resulting from 
immunosuppression  (Shizuru et al. 2005).  Also, there are risks such as infection and 
splenomegaly to donors of BM and MPB grafts. For hUCB transplantation, many 
problems result from the fact that HSCs are limited in number from this source, 
restricting this therapy primarily to pediatric patients (Broxmeyer 2006; Lewis 2002).  
These clinical problems imply that the mechanism controlling engraftment of HSCs in a 
transplant recipient is not fully understood. Currently, there are many areas of 
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hematopoietic research directed at understanding HSC functions such as self-renewal, 
differentiation, homing/migration and engraftment and applying this information to the 
clinical problems still associated with HCT. Two branches of research addressing these 
problems include (1) modulating HSC homing/engraftment by affecting the SDF-1-
CXCR4 axis and (2) modulating growth signaling pathways leading to expansion of 
HSCs ex vivo. Previous work done in each of these areas will be summarized in more 
detail in order to give adequate background for the current study. 
Enhancement of homing/engraftment of HSCs by modulating the SDF-1-CXCR4 axis: 
one strategy to improve HCT efficacy 
If homing and engraftment can be enhanced, the time to recovery of hematopoietic 
lineages can be reduced resulting in less engraftment failures and better overall survival, 
especially in hUCB transplantation (Broxmeyer 2006; Lewis 2002). A better 
understanding of factors which affect migration and homing of HSCs is important in 
solving these problems and expanding HSC clinical applications.  
Homing is defined as the ability of HSCs, once injected into the peripheral circulation, to 
move out of the PB and into the BM stroma where niches conducive to HSC expansion 
and differentiation exist. This process is thought to occur shortly after transplantation, 
often within 24 hours and before the cells have had a chance to divide (Lapidot et al. 
2005). Understanding how HSCs migrate in vitro and in vivo has direct clinical 
relevance, since once transplanted, the cells need to leave the PB and enter delicate 
niches in the BM stroma (Chute 2006; Lapidot et al. 2005). In addition, stable long-term 
engraftment is dependent upon adequate homing of the HSCs into their niches (Chute 
2006; Lapidot et al. 2005). Enhancing this migration from the PB into the BM is proposed 
as a way to increase the overall engraftment of the cells, leading to fewer failures and 
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better survival (Chute 2006; Christopherson et al. 2004). This strategy is especially 
applicable in hUCB transplantation where low numbers of HSCs contained in the graft 
often limit this therapy to younger recipients. Enhancing the homing and engraftment 
efficiency of hUCB cells could expand this therapy for use in older or larger patients 
(Christopherson et al. 2002; Christopherson et al. 2004; Campbell et al. 2007b).  
Migration and homing of HSCs are processes dependent upon extracellular signals from 
growth factors, adhesion molecule/ligand interactions and chemokines (Broxmeyer 
2008; Laird et al. 2008; Yaniv et al. 2006; Lapidot et al. 2005; Cancelas et al. 2006).  
Hematopoietic chemokines such as SCF produced by stromal cells affect homing of 
transplanted cells, by mechanisms including the upregulation of extracellular matrix 
adhesion molecules (Lapidot et al. 2005; Hart et al. 2004). Adhesion molecules, such as 
members of the integrin and selectin families, are known to play important roles in 
movement of cells out of the blood vessel and into the BM stroma, and inhibition of these 
interactions leads to impaired in vivo homing and engraftment (Hidalgo et al. 2002; van 
der Loo et al. 1998; Chute 2006; Kollet et al. 2001) 
For our current studies, we focused on the important role of chemokines which are small 
protein cytokines responsible for stimulating in vitro migration and in vivo homing of 
various cell types. These proteins act on cell surface receptors, in many cases of the G-
protein linked type, and stimulate directed movement of the cell towards a gradient. In 
the body, these protein mediators are responsible for physiological processes such as 
lymphocyte movement into lymph nodes, inflammatory cell recruitment at sites of 
inflammation, anchorage of HSCs in the BM stroma and metastasis of many different 
types of cancer cells from the original tumor to distant tissue beds (Zlotnik and Yoshie 
2000; Baggiolini 1998; Sallusto et al. 1998; Broxmeyer 2001; Broxmeyer 2008; Murphy 
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1994). The chemokine stromal-derived factor 1 (SDF-1)/CXCL12 and its receptor 
CXCR4 play crucial roles in these processes, including allowing human HSCs to get to 
their BM destination (Peled et al. 1999; Lapidot et al. 2005; Cottler-Fox et al. 2003). 
Human and mouse phenotypic HSCs express the receptor CXCR4 and migrate towards 
an SDF-1 gradient in vitro (Aiuti et al. 1997; Kim and Broxmeyer 1998; Wright et al. 
2002; Rosu-Myles et al. 2000; Christopherson et al. 2002; Christopherson et al. 2004). 
Inhibition of the SDF-1-CXCR4 interaction by antibodies to CXCR4 decreases 
engraftment of immunodeficient mice by human CD34+ cells; conversely, upregulation of 
CXCR4 on the CD34+ cells by cytokines stimulation or transduction enhances in vivo 
engraftment (Peled et al. 1999; Kahn et al. 2004; Brenner et al. 2004).  
Homing and engraftment are complex processes, and it is clear that the SDF-1 CXCR4 
axis is not the only player involved; however, modulation of this axis does dramatically 
affect HSC movement and behavior. 
Modulation of SDF-1 – CXCR4 axis by the CD26/dipeptidylpeptidase IV (DPPIV) 
Enzyme 
In vivo, many chemokines do not exist as a pool of full-length proteins. Substantial 
evidence has shown that chemokines can be processed, especially at their N-terminus, 
by proteases and peptidases (Baggiolini 1998; Crump et al. 1997; Clark-Lewis et al. 
1995). This results in a mixed pool of cleaved and full-length molecules. The enzyme 
dipeptidylpeptidase IV/CD26 can cleave the N-terminus from many chemokine 
substrates, including regulated on activation, normal T cell expressed and secreted  
(RANTES/CCL5); granulocyte chemotactic protein-2 (GCP-2/CXCL6); macrophage 
inflammatory protein-1β (MIP-1β/CCL4); macrophage-derived chemokine 
(MDC/CCL22); the CXCR3 ligands monokine induced by IFN-γ (Mig/CXCL9), IFN-γ-
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inducible protein-10 (IP-10/CXCL10) and IFN-inducible T-cell α-chemoattractant (I-
TAC/CXCL11); eotaxin/CCL11; macrophage inflammatory protein-1α ( MIP-
1α/LD78β/CCL3-L1) and stromal derived factor-1 (SDF-1/CXCL12) (Oravecz et al. 1997; 
Proost et al. 1998a; Struyf et al. 1998a; Guan et al. 2004; Guan et al. 2002; Proost et al. 
1999; Struyf et al. 1998b; Struyf et al. 1999; Proost et al. 2001; Ludwig et al. 2002; 
Proost et al. 2000; Struyf et al. 2001; Proost et al. 1998b; Shioda et al. 1998; Ohtsuki et 
al. 1998). In most cases, the cleavage of an individual chemokine by CD26 produces a 
form that has altered functional activity, summarized in Table 1.  
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CD26-Truncated Chemokine Functional Changes 
RANTES/CCL5 (aa 3-68) Change in receptor selectivity
Decreased CCR1 activity
Decreased CCR3 activity
Equal or Increased CCR5 activity
MIP1β/CCL4 (aa 3-69) Change in receptor specificity
Addition of CCR1 and CCR2b activity
No change in cognate CCR5 activity
MDC/CCL22 (aa 3-69 and aa 5-69) Decreased activation of CCR4
Possible activity via unidentified receptor on monocytes
Eotaxin/CCL11 (aa 3-74) Minimal decrease in CCR3 binding
Loss of CCR3 activation 
MIP1α/LD78β/CCL3-L1 (aa 3-70) Increased activity through receptors CCR5 and CCR1
Decreased activity through CCR3
GCP-2/CXCL6 (aa 3-77) No changes in intracellular calcium release from neutrophils 
IP-10/CXCL10 (aa 3-77) CXCR3 binding and activation are significantly reduced
I-TAC/CXCL11 (aa 3-73) Binding to CXCR3 is modestly reduced 
CXCR3 intracellular calcium release is significantly reduced
CXCR3 internalization is modestly reduced 
Mig/CXCL9 (aa 3-103) No significant decrease in CXCR3 binding nor intracellular 
calcium release 
SDF-1/CXCL12 (aa 3-68) Substantially reduced activation of CXCR4
Binding to CXCR4 is modestly reduced 
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Table 1: CD26/DPPIV effect on select chemokine functions. Shown are various 
chemokines known to be cleaved by CD26 and the resulting changes in activity and/or 
receptor binding. 
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The role of CD26 in the physiological cleavage of SDF-1/CXCL12 was established by a 
series of studies published by various researchers (Proost et al. 1998b; Shioda et al. 
1998; Ohtsuki et al. 1998). These groups examined the effect of CD26-mediated SDF-
1/CXCL12 cleavage on chemotaxis and CXCR4 activation in both cell lines and primary 
peripheral blood cells. They demonstrated that CD26 could indeed cleave SDF-
1/CXCL12 under physiological conditions in transfected cell lines overexpressing CD26; 
and recombinant soluble CD26 could cleave SDF-1/CXCL12 in vitro. CD26/DPPIV 
action produced SDF-1/CXCL12 (aa 3-68), a truncated molecule which lost its ability to 
induce chemotaxis. In intracellular calcium release assays the truncated SDF-1/CXCL12 
(aa 3-68) had some ability to desensitize subsequent signals from full-length SDF-
1/CXCL12, but this was at significantly higher concentrations of the cleaved form 
compared to full-length (Proost et al. 1998b). This desensitization can be explained by a 
mechanism in which SDF-1/CXCL12 (3-68) cannot signal through the receptor but can 
bind, albeit less efficiently, to CXCR4, and is supported by detailed structure-functional 
experiments showing that the N-terminus of SDF-1/CXCL12 is important for CXCR4 
receptor binding and activation, with activation being highly dependent on the first two 
residues (Crump et al. 1997). In fact, loss of the first two residues, resulting in the form 
SDF-1/CXCL12 (aa 3-68), abolishes CXCR4 activation but only modestly impairs 
CXCR4 binding (about a 10-fold decreased binding affinity) (Crump et al. 1997). 
Presumably, the antagonism of CXCL12 (aa 3-68) can be explained by a steric 
hindrance mechanism. An alternative explanation for the desensitizing effect of cleaved 
SDF-1 (aa 3-68) could be an ability to downmodulate CXCR4 by activating non-
canonical signaling pathways not measured by the calcium release functional assays 
used in these studies, a phenomenon supported by studies of at least one other 
chemokine (Ludwig et al. 2002).  
13 
 
Given the importance SDF-1- CXCR4 interactions in HCT, the physiological 
consequences of CD26 mediated SDF-1 cleavage on mouse and human HSC 
chemotaxis, mobilization and in vivo engraftment/repopulation using various CD26 
inhibitors and CD26-knockout mice was studied. Specific CD26 inhibitors Diprotin A and 
Val-Pyr were used in these studies, in addition to the CD26 -/- knockout mouse  
(Christopherson et al. 2004). Kent Christopherson II and colleagues in the Broxmeyer 
laboratory showed that immature HPCs/HSCs  from both human cord blood (CB)  and 
mouse bone marrow (BM) expressed CD26 on their surface (Christopherson et al. 2002; 
Christopherson et al. 2003; Christopherson et al. 2004).  About 8% of hUCB CD34+ cells 
were positive for surface expression of CD26 (Christopherson et al. 2002). CD26 was 
present on the surface of 70% of phenotypic c-kit+ sca-1+ lin- (KSL) mouse HSCs 
(Christopherson et al. 2003). The CD26 expressed on HSCs was functional as 
measured by an in vitro enzymatic assay utilizing a chromogenic reaction 
(Christopherson et al. 2003; Christopherson et al. 2002; Christopherson et al. 2004; 
Christopherson II et al. 2007).  
In studies on mouse HSCs/HPCs, Diprotin A pre-treatment enhanced SDF-1/CXCL12 
chemotaxis in vitro (Christopherson et al. 2003; Christopherson et al. 2004). In addition, 
purified truncated SDF-1/CXCL12 (aa 3-68) was unable to stimulate chemotaxis, and 
further, pre-incubation of these cells with the truncated form antagonized chemotaxis to 
full-length SDF-1/CXCL12 (Christopherson et al. 2003). This suggests that the cleaved 
SDF-1 binds to CXCR4 and blocks activation by the full-length molecule.  
In addition to in vitro chemotaxis, CD26 was found to have a role in modulating G-CSF 
mediated mobilization in vivo, a process involving the SDF-1 − CXCR4 axis (Lapidot and 
Petit 2002; Broxmeyer et al. 2005). Two different strains of mice (C57BL/6 and DBA/2) 
were treated with the CD26 inhibitor Diprotin A or Val-Pyr during G-CSF induced 
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mobilization and the extent of mobilization of HPCs was measured by colony-forming 
assays using peripheral blood cells. Both CD26 inhibitors reduced the numbers of G-
CSF mobilized HPCs in the periphery in both strains of mice (Christopherson et al. 
2003). In further studies using CD26 knockout mice, the absence of CD26 substantially 
decreased normal G-CSF induced mobilization when compared to wild-type mice 
(Christopherson et al. 2006). The mechanism of CD26 in mobilization is not fully 
elucidated, but presumably the inhibition of CD26 could strengthen anchoring of 
HSCs/HPCs by the SDF-1 − CXCR4 axis in the BM stroma, thus reducing their tendency 
to move out into the PB in response to G-CSF induced mobilization (Christopherson et 
al. 2003). 
An important role for CD26 in modulating mouse HSC in vivo repopulation was further 
established by inhibition of CD26 on donor cells or using CD26-/- donor cells in congenic 
competitive repopulation assays. These assays involve mixing donor and competitor 
cells from congenic mouse strains differing at the CD45 locus, a marker present on most 
hematopoietic cells, and transplanting these cells into lethally irradiated congenic 
recipients (often expressing the same CD45 marker as competitor cells). The CD45 
markers can be distinguished and followed monthly in the PB by using flow cytometry. 
This in vivo assay is considered to be the gold-standard for assessing HSC function. 
Pre-treating donor HSC/HPCs with the CD26 inhibitors Diprotin A or Val-Pyr for short 
periods before transplantation significantly and dramatically increased their short-term 
homing and competitive repopulation of primary and secondary recipients, suggesting 
that the engraftment of HSCs was enhanced by this treatment (Christopherson et al. 
2004). Secondary transplantation of BM cells pre-treated with Diprotin A likely results 
from a higher number of HSCs in the primary transplant recipients and not from any 
long-term effect of Diprotin A, since this is a reversible inhibitor. Furthermore, CD26-/- 
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mouse donor HSCs were transplanted and found to have increased homing and 
engraftment compared to wild-type (Christopherson et al. 2004). The effect of CD26 
inhibition on engraftment and repopulation of donor cells was seen under conditions of 
limiting cell numbers; that is, in these mouse models CD26 inhibition can lower the 
threshold needed to get adequate repopulation and survival of lethally irradiated 
recipient mice (Christopherson et al. 2004). The CD26 inhibitors used in these studies 
are short-lasting in duration, about 4 hours in pre-treated hematopoietic cells 
(Christopherson et al. 2004), but the net effect of their use is to increase long-term 
engraftment of donor cells. This could be explained by a mechanism in which the 
immediate effect of CD26 inhibition is to increase the efficiency of homing of HSCs to the 
BM of recipients, akin to transplanting higher numbers of HSCs. Since long-term 
engraftment is reliant upon numbers of HSCs able to home and take residence in the 
BM, this short-term treatment would have consequences on stable engraftment. Other 
processes such as adhesion or retention in the BM could be affected by this treatment; 
however, we believe homing is the most logical mechanism involved (Christopherson et 
al. 2004).  
The effect seen on engraftment in mouse transplants has been reproduced in two 
studies by independent laboratories. The first group showed that inhibition of CD26 
could enhance engraftment of limiting numbers of virally-transduced hematopoietic cells 
expressing a recombinant allogeneic MHC class I molecule (Tian et al. 2006). This 
group showed that the enhanced level of engraftment seen in animals transplanted with 
Diprotin A pre-treated cells correlated with decreased rejection of an allogeneic skin graft 
(Tian et al. 2006). The second independent group showed that CD26 inhibition 
significantly increased homing and engraftment in the context of non-ablative, allogeneic 
in utero hematopoietic-cell transplantation (IUHCT). Specifically, they were able to show 
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that short-term homing (4 hours or 48 hours) of transplanted whole BM and purified 
HSCs pre-treated with Diprotin A was enhanced, a higher percentage of mice with 
detectable engraftment was found, the level of stable engraftment was increased up to 6 
months post-transplant, and the Diprotin A treated cells could dramatically outcompete 
non-treated congenic donor cells in competitive IUHCT experiments (Peranteau et al. 
2006).  
These results strongly support a model where inhibition of CD26 activity enhances the 
ability of donor HSCs to transplant conditioned recipients. This treatment could have 
clinical relevance in many different transplant situations; however, it could have an 
immediate impact in the field of hUCB transplantation where, as mentioned previously, 
donor HSCs are of small number and limit the therapy to pediatric patients. There is 
evidence that CD26 inhibition enhances chemotaxis/migration of hUCB CD34+ cells in a 
similar fashion as mouse HSCs, but no evidence that inhibition of CD26 on CD34+ cells 
has a similar effect on in vivo engraftment as in the mouse system (Christopherson et al. 
2002). Extending on previous mouse transplantation studies by determining the role of 
CD26 in in vivo engraftment of hUCB CD34+ HSCs is one of the goals of my thesis 
project.  
Strategies to expand HSCs ex vivo and enhance HCT 
Another way in which researchers are attempting to solve the problems associated with 
HCT and apply this therapy to a broader patient population is by using strategies aimed 
at expanding hematopoietic stem and progenitor cells ex vivo while still maintaining their 
full functional repertoire. Cells expanded in this fashion could be transduced with viral or 
other types of vectors in order to complement a genetic defect, as in the case of Fanconi 
Anemia, or could be used to transplant many recipients from one donor. Additionally, 
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being able to expand HSCs ex vivo could be accompanied with treatments aimed at 
suppressing reactive T cell activity or enhancing anti-tumor specific T cell activity, 
strategies which would help decrease GVHD or increase graft versus tumor response, 
respectively.  
All of these goals rely upon a more complete understanding of which molecular 
pathways modulate proliferation, quiescence, differentiation, survival and metabolism in 
normal HSCs and HPCs and how these pathways interact with and influence each other. 
We will give an overview of selected molecules that recently have been used to expand 
HSCs in pre-clinical studies and discuss our interest in the role of a novel Ras 
homologue, Rheb2, and its downstream signaling pathway, mTOR, in HSC expansion.  
Cytokines and HSC expansion 
The use of cytokines, including stem cell factor (SCF), thrombopoietin (TPO), Flt3L, IL-3, 
IL-6 and others can expand immature mouse and human hematopoietic cells ex vivo 
(Gammaitoni et al. 2003; Bodine et al. 1989; Bodine et al. 1992; Petzer et al. 1996; 
Bhatia et al. 1997a; Heike and Nakahata 2002). However, their ability to expand long-
term repopulating cells is not clear, as many of these early studies relied on spleen 
colony-forming assays and long-term cultures to assess stem cell function, both of which 
more appropriately measure short-term stem cells or multipotent progenitors. 
Furthermore, there is no clear clinical data showing an advantage in terms of 
repopulation in expanding human HSCs before transplantation (Heike and Nakahata 
2002).   
Notch and HSC expansion 
More recent studies on the use of extracellular signaling molecules to expand HSCs 
have focused on the developmentally relevant membrane-bound Notch. The receptor 
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Notch-1 activation by the ligands Jagged-1 or Delta-1 expressed by BM stromal cells 
including osteoblasts expanded immature human and mouse hematopoietic cells in vivo 
(Karanu et al. 2000; Calvi et al. 2003; Ohishi et al. 2002). In select studies, transducing 
mouse HSCs with vectors overexpressing Notch-1 led to expansion of repopulating 
HSCs (Stier et al. 2002). However, Notch-1 hyperactivation impaired the ability of mouse 
HSCs to differentiate normally as skewing of myeloid and lymphoid lineages, with a 
preference for lymphoid cells, was found in these studies (Stier et al. 2002; Ohishi et al. 
2002). Better regulation of Notch-1 activity is necessary before clinical use of these 
molecules is possible. 
Transcription factors and HSC expansion 
Analysis of the transcription factor HoxB4 has shed light on another intracellular pathway 
important in the expansion of HSCs. HoxB4 is a member of the Hox family of 
transcription factors expressed in HSCs (Sorrentino 2004). Studies performed using 
mouse HSCs overexpressing HoxB4 found expansion of HSCs in vivo in mouse 
transplant assays as well as in vitro under liquid culture conditions (Sauvageau et al. 
1995; Antonchuk et al. 2002). Additional studies using a Tat-HoxB4 fusion protein found 
that mouse HSC expansion could be accomplished without the need of a viral vector, by-
passing the biological and safety concerns associated with viral gene therapy (Krosl et 
al. 2003). Problems associated with HoxB4 induced expansion include the possibility of 
leukemic transformation, observed using other Hox family members, and impairment of 
normal blood cell differentiation (Perkins and Cory 1993; Thorsteinsdottir et al. 1997; 
Brun et al. 2003; Schiedlmeier et al. 2003).  
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Wnt and HSC expansion 
The Wnt-β catenin pathway has recently been studied for its role in expanding HSCs 
(Sorrentino 2004). Soluble Wnt proteins activate the cell-surface receptor frizzled which 
can then, through a series of intracellular mediators, inhibit the degradation of β catenin 
allowing it to translocate to the nucleus and act as a transcription factor for a host of 
genes involved in cell proliferation, differentiation and other processes. The β catenin 
pathways is often altered in malignancies, including leukemia (Sorrentino 2004). In 
studies on both mouse and human hematopoietic cells, researchers found that addition 
of soluble Wnt proteins expanded HSCs and/or HPCs in liquid cultures (Willert et al. 
2003; Austin et al. 1997; Van Den Berg et al. 1998; Murdoch et al. 2003). Candidate Wnt 
proteins used in these studies were Wnt-1, Wnt-5a, Wnt-10b and Wnt3a for mouse cells, 
and Wnt-5a, Wnt-2b and Wnt-10b for human cells. At least two of these Wnt proteins, 
Wnt3a for mice and Wnt5a for humans had some ability to expand cells capable of in 
vivo repopulation of recipient animals (Willert et al. 2003; Murdoch et al. 2003). Although 
soluble Wnt proteins can expand HSCs ex vivo, there is evidence that sustained Wnt 
activation leads to a loss of HSC repopulating activity, potentially a major concern in any 
therapy aimed at treating humans (Fleming et al. 2008).  
Ras family members and HSC expansion 
The ras family of GTPase intracellular signaling proteins contains members which play 
important roles in HSC functions and malignant transformation. These GTPase 
molecules and their associated signaling pathways remain interesting targets for 
modulating HSC expansion and repopulating ability. We have focused on a novel ras 
related molecule and activator of the mammalian target of rapamycin (mTOR) pathway, 
Rheb2, for our current studies on hematopoietic cell growth and repopulation.  
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Ras intracellular GTPase proteins act as molecular switches inside cells, alternating 
between GTP-bound active and GDP-bound inactive forms in response to signals from 
growth factors, including hematopoietic cytokines such as SCF (Linnekin 1999). Ras 
family members such as K-ras and N-ras are well-known for their role as oncoproteins in 
human leukemias and proliferative blood disorders, in most cases resulting from 
mutation of wild-type protein leading to constitutively GTP-bound ras (Scheele et al. 
2000; Van Meter et al. 2007). In normal mouse or human hematopoietic stem and 
progenitor cells, expression of mutant, hyperactive K-ras or N-ras causes 
hyperproliferation, myeloid skewing, including myeloproliferative disease in mice, and 
alteration of many intracellular signaling pathways, while loss of normal K-ras leads to 
defects in mouse fetal liver erythropoiesis (Braun et al. 2004; Van Meter et al. 2007; 
Shen et al. 2004; Tuveson et al. 2004; Khalaf et al. 2005; MacKenzie et al. 1999). Loss 
of neurofibromin 1 (NF1), the ras GAP protein, leads to hyperactive ras signaling and 
altered growth of hematopoietic cells, including hypersensitivity to hematopoietic growth 
factors (Bollag et al. 1996). Other ras family members have important roles in 
hematopoiesis. Members of the Rho family, such as rhoH, rac1 and rac2, have profound 
roles in hematopoietic cell migration and chemotaxis. Loss of rac1 and rac2 leads to 
defective mouse hematopoietic cell migration, while loss of rhoH leads to enhanced 
migration through a mechanism mediated by rac1 (Cancelas et al. 2006; Chae et al. 
2008; Gu et al. 2003).   
Rheb2: a potential target in HSC expansion 
The role of a novel ras subfamily, Ras homologue enriched in brain (Rheb), in 
mammalian hematopoiesis has not been extensively studied. Interestingly, Rheb2, one 
member of the Rheb family, has been found in a subtractive cDNA library to be 
preferentially expressed in immature mouse HSCs compared to mature cells (Ivanova et 
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al. 2002), indicating that this molecule may play a role in HSC functions such as self-
renewal and/or differentiation. Human Rheb proteins are ubiquitously expressed and are 
elevated in many types of tumors (Basso et al. 2005; Yuan et al. 2005). Like most Ras 
proteins, Rheb proteins are small (about 20kDa) GTPase molecules which can cycle 
between active GTP-bound and inactive GDP-bound forms and act primarily in cells as 
upstream activators of the mammalian target of rapamycin (mTOR) pathway, a pathway 
involved in cell growth, proliferation and survival of various cell types in organisms as 
diverse as yeast and man (Wullschleger et al. 2006; Fingar and Blenis 2004; Tee et al. 
2005).  
Rheb2 and mTOR signaling 
Both Rheb family members, Rheb1 and Rheb2, activate the mTOR serine/threonine 
kinase by mechanisms not fully known, but which rely on binding of active GTP-bound 
Rheb to mTOR (Long et al. 2005b; Long et al. 2005a). The mTOR pathway is involved in 
different aspects of HSC biology. Many of the molecules discussed above as capable of 
HSC expansion, including growth factor cytokines (Flt3Ligand, SCF, TPO, and IL-3), 
Wnt proteins and Notch proteins are able to activate the mTOR pathway, indicating the 
involvement of this pathway mediating responses to these factors (Chan et al. 2007; 
Mungamuri et al. 2006; Wieman et al. 2007; Choo et al. 2006; Inoki et al. 2006). In 
normal mouse megakaryocytes, mTOR activation by thrombopoietin is needed for end-
stage differentiation of platelets, measured by expression of phenotypic cell surface 
antigens (Raslova et al. 2006). mTOR also mediates IL-3 dependent proliferation in the 
mouse myeloid progenitor cell line 32D (Cruz et al. 2005). In studies on various 
hematologic tumors and malignancies, the use of rapamycin or rapamycin analogues, 
often in combination with other treatments, increased cell death, indicating that mTOR is 
important for their survival (Bertrand et al. 2005; Xu et al. 2005a; Xu et al. 2005b; Follo 
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et al. 2007; Hammerman et al. 2005). Finally, mTOR hyperactivation in the context of the 
tumor suppressor phosphatase PTEN conditional knockout  mouse was important for 
leukemic transformation, and for expansion of normal HSC numbers followed by their 
exhaustion (Yilmaz et al. 2006; Zhang et al. 2006).  
Rheb proteins lie upstream of mTOR in the PI3K-Akt signaling pathway 
Rheb proteins, like most small GTPase molecules, are directly regulated by two major 
classes of proteins: the GTP exchange factors (GEFs) and the GTPase activating 
proteins (GAPs). GEFs increase the GTP loading of GTPase molecules, thereby 
activating them, while GAPs accelerate their intrinsic GTPase activity accelerating 
catalysis of GTP to GDP and inactivating protein. Recent evidence from drosophila 
suggests that the protein translationally controlled tumor protein (TCTP) is the putative 
Rheb GEF (Hsu et al. 2007). Interestingly, the Rheb GAP is the tuberous sclerosis 
complex (TSC), a heterodimer of TSC1 and TSC2 individual proteins (Wullschleger et al. 
2006; Astrinidis and Henske 2005). The function of TSC is impaired in patients afflicted 
with the clinical syndrome tuberous sclerosis (TS), an autosomal dominant, primarily 
pediatric genetic disease characterized by benign hamartomas, i.e. benign solid tumors, 
in various locations throughout the body including the brain causing mental retardation 
and other sequelae depending on tumor location (Astrinidis and Henske 2005). Rheb 
proteins respond to upstream signals coming mainly from growth factors acting through 
the PI3K-PIP3-PDK1-Akt pathway. Various growth factors activate cell surface receptors 
such as tyrosine kinase receptors leading to activation of PI3K which converts PIP2 to 
PIP3, resulting in activation of PDK1 and finally Akt (Morgensztern and McLeod 2005; 
Cruz et al. 2005; Desponts et al. 2006; Shaheen 2005; Steelman et al. 2008). Akt is an 
intracellular kinase capable of interacting with and phosporylating various downstream 
effectors. As one of its downstream effectors, TSC2 is phosphorylated by Akt, leading to 
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inactivation of the TSC GAP activity (Wullschleger et al. 2006; Astrinidis and Henske 
2005). This leads to a greater proportion of GTP-bound active Rheb, capable of 
activating mTOR downstream (Li et al. 2004a; Li et al. 2004b; Astrinidis and Henske 
2005).  
mTOR forms two distinct complexes in cells: mTOR complex 1 and complex 2 
(mTORC1 and mTORC2) which differ in their components, sensitivity to rapamycin and 
downstream effectors (Wullschleger et al. 2006). The mTOR kinase is common to both 
complexes in mammalian cells. mTOR bound with raptor and mLST8 forms mTORC1, 
which is sensitive to rapamycin inhibition and activates downstream targets primarily 
involved in enhancing cellular translation, including ribosomal S6 protein kinase 1 
(S6K1) and 4E-binding protein (4E-BP) (Wullschleger et al. 2006). Phosphorylation of 
S6K1 enhances general translation by increasing the synthesis of ribosomal proteins. 
Phosphorylation of 4E-BP relieves inhibition on initiation factor 4E (eIF-4E) which can 
then initiate translation (Wullschleger et al. 2006). mTORC1 is involved in other cellular 
processes, including inhibition of autophagy and enhancing the function of transcription 
factors mainly involved in stress responses (Wullschleger et al. 2006). There is recent 
evidence suggesting that mTORC1 activates STAT1, STAT3 and PPARγ transcription 
factors (Wullschleger et al. 2006). mTOR bound with rictor, hSIN1 and mLST8 forms 
mTORC2, a complex which is insensitive to rapamycin and activates proteins such as 
Rho involved in actin cytoskeletal dynamics (Wullschleger et al. 2006). Negative and 
positive feedback loops acting on the Akt pathway from mTORC1 and mTORC2, 
respectively, are now beginning to be appreciated for their roles in modulating mTOR 
signaling (Wullschleger et al. 2006).The majority of Rheb effects are attributed to its 
ability to activate mTORC1, and a recent study found no activity of Rheb1 on mTORC2 
(Huang et al. 2008). Rheb2 has not been studied for activity on mTORC2. There is also 
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evidence to suggest that Rheb1 can have negative effects on signaling through the Raf-
MAP kinase pathway (Karbowniczek et al. 2006; Im et al. 2002). This function has not 
been described for Rheb2 and the functional significance of this activity is not clear. 
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AIMS 
Strategies to enhance HCT include modulation of homing/engraftment by altering the 
SDF-1-CXCR4 axis in vivo and manipulation of signaling proteins in cells responsible for 
hematopoietic cell expansion and repopulating ability. We chose to investigate these 
strategies by focusing on two aims. 
 
AIM 1: Determine the role of CD26 inhibition in increasing human umbilical cord blood 
CD34+ cell engraftment using a xenogeneic mouse transplantation model, and 
furthermore, assess the effect of CD26 inhibition on multilineage reconstitution in vivo. 
 
AIM 2: Determine the role of the novel Ras-related molecule Rheb2 in expansion of 
mouse hematopoietic cells and engraftment of mouse HSCs using congenic murine 
transplantation models. 
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MATERIALS & METHODS 
Part I 
Human umbilical cord blood CD34+ cell isolation 
Human CB was obtained from the umbilicus after full term births at Wishard Hospital, 
Indianapolis, IN.  Cord blood was diluted 1:1 with Phosphate buffered saline (PBS) 
(Lonza, Switzerland) and mononuclear cells were isolated by Ficoll-Paque™ Plus 
(Amersham Biosciences, Piscataway NJ, USA) separation as previously described 
(Broxmeyer 2006). CD34+ cells were isolated by positive magnetic selection with Miltenyi 
MACS magnetic activated cell sorting kit (Miltenyi Biotec, Germany). The CD34+ purity 
was analyzed by flow cytometric staining with anti-human CD34 antibodies (BD 
Pharmingen, Franklin Lakes, NJ or Dako Cytomation, Denmark). The cell purity was 
greater than 90% in experiments 1 and 2, and less than 40% in experiment 3. 
Transplantation of NOD/SCID mice 
 NOD/SCID mice (8-10 wk old) were obtained from the Indiana University School of 
Medicine xenograph core facility and were exposed to a sub lethal dose of 300 cGy total 
body irradiation 4 hours before transplantation. The CD34+ cells, prepared as described 
above, were washed once with PBS and resuspended in PBS for transplantation by tail-
vein injection. All animals were fed food pellets containing doxycycline 1 week before 
transplantation and maintained on this diet approximately 4 weeks after transplantation. 
Staining of mouse bone marrow cells for engraftment 
Mouse BM cells were isolated from both femurs using aseptic procedures. 1x106 cells 
were resuspended in FACS staining buffer (SB) (PBS + 2% FBS + 0.5 mM EDTA) and 
were stained with either anti-human CD45-PE (BD Pharmingen) or isotype control-PE 
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antibodies (BD Pharmingen), incubated for 30 minutes in the dark at 4°C, washed twice 
with PBS containing 2% BSA, and resuspended in PBS containing 1% para-
formaldehyde for analysis by flow cytometry. About 40,000 to 50,000 events were 
collected for each sample. 
For staining with multiple hematopoietic markers, 5x105 cells were resuspended in SB 
and stained with anti-human CD38-FITC, anti-human CD34-PE and anti-human CD45-
APC antibodies (BD Pharmingen), or with anti-human CD19 PE, anti-human CD33 FITC 
and anti-human CD45 APC antibodies (BD Pharmingen). Isotype control stainings were 
done with isotypic FITC, PE and APC conjugated antibodies (BD Pharmingen). Cells 
were washed twice with PBS containing 2% BSA and resuspended in PBS with 1% 
para-formaldehyde. 20000 events were collected for each sample.  
Staining of human CB subsets for CD26 expression 
CB mononuclear cells were isolated by Ficoll-Paque™ Plus separation, and CD34+ cells   
isolated using Miltenyi MACS kit were resuspended in SB and stained with anti-human 
CD34, anti-human CD38 and anti-human CD26 antibodies (BD Pharmingen, Caltag and 
Dako Cytomation). Control stainings were performed with isotype antibodies (BD 
Pharmingen and Dako Cytomation). Cells were washed twice with PBS containing 2% 
BSA and resuspended in PBS containing 1% para-formaldehyde. At least 8000 events 
were collected for each sample.  
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Part II 
Cloning of Rheb2-Mieg3 retroviral vector 
The full cDNA of mouse Rheb2 was acquired from ATCC (BC016521; MGC 27835) in 
the vector pCMV-Sport6. Primers were designed to amplify the Rheb2 cDNA containing 
a StuI RE site and Flag-tag at the 5’ end and an XhoI RE site at the 3’ end, with Rheb2 
flanking sequences in order to amplify the product. The Rheb2 cDNA was PCR amplified 
using PuRe Taq PCR beads (Amersham Biosciences, Piscataway NJ, USA). This PCR 
product was cloned into the vector pCR2.1 using the kit TA cloning kit (Invitrogen). 
Correct cloning of the product was verified by StuI and XhoI RE digests, as well as DNA 
sequencing (Indiana University School of Medicine (IUSM) DNA sequencing core facility, 
Indianapolis IN, USA). The Rheb2 cDNA was cut out of this vector by StuI and XhoI RE 
digestion and ligated into linearized Mieg3 retroviral vector obtained from Dr. Wen Tao in 
our laboratory using DNA ligase enzyme (Invitrogen) following the manufacturer’s 
protocol. Accurate cloning of Rheb2 cDNA, including alignment in Mieg3 vector and 
accurate sequence was verified by StuI and XhoI RE digestion as well as DNA 
sequencing (IUSM DNA sequencing core facility). Production of full-length Rheb2 protein 
by this vector was confirmed by Western blot of NIH-3T3, BaF3 and 32D cell lysates as 
explained below. Mieg3 empty vector was used as a control in all experiments. 
Retroviral Transduction and Supernatant production 
The murine stem cell virus (MSCV) retroviral vector Mieg3 is a bicistronic vector that 
expresses enhanced green fluorescent protein (eGFP) controlled by the internal 
ribosome entry site (IRES) and has been previously used to transduce mouse 
hematopoietic cells (Tao et al. 2004). Retroviral supernatants were prepared by 
transfection of 8 µg per 10 cm2 culture dish Mieg3 (empty vector) or Rheb2-Mieg3 
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plasmid DNA into Phoenix Ecotropic 293T cells (Nolan Lab, Stanford CA, USA) using 
lipofectamine (Invitrogen, Carlsbad CA, USA). Medium was changed after 12-16 hours 
to fresh DMEM + 10% FBS (Hyclone, Logan UT, USA). Retroviral supernatants were 
collected 24 and 48 hours later, filtered using 0.45 µm syringe filters, aliquoted for 
titering and stored at -80°C.  
Retroviral Titers on NIH 3T3 cells 
Trypsinized NIH 3T3 cells were plated in individual wells of a 6-well plate at a 
concentration of 30,000 cells per 3 mls of IMDM + 10% FBS. The following day, either 
20 or 100 µl of retroviral supernatants was added to individual wells in 1.5 mls complete 
IMDM +  5 µg/ml polybrene transduction reagent (Chemicon International, Billerica, MA 
USA). In addition, the cell number per well was calculated at this time by trypsinizing 3 
wells of NIH 3T3 cells, counting the total cell number by trypan blue exclusion and 
dividing by 3 to get the cell number per well. Medium was changed after 24 hours to 
fresh complete IMDM, and cells were harvested by trypsin 24 hours later. The percent 
GFP+ cells was determined by FACS, and the titers were calculated by multiplying the 
proportion of GFP+ cells by the total number of cells at time of infection and dividing that 
number by the volume of retroviral supernatant added (either 0.02 or 0.1 ml) to get the 
number of viral particles per ml.  
Transduction of BaF3 and 32D cell lines 
BaF3 cells were maintained in RPMI + 10% FBS + 0.25 ng/ml mouse IL-3 (R&D 
Systems, Minneapolis, MN). 32D cells were maintained in RPMI + 10% FBS + 10 ng/ml 
mouse IL-3 (R&D Systems). 
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For BaF3 and 32D cell transduction, cells were resuspended in Mieg3 or Rheb2-Mieg3 
supernatants containing mouse IL-3 (0.25 ng/ml for BaF3; 10 ng/ml for 32D) and plated 
on retronectin coated wells of a 24-well plate pre-loaded with Mieg3 or Rheb2-Mieg3 
supernatants. Transductions were repeated the following day. The cells were FACS 
sorted for GFP expression and expanded in medium containing IL-3 to create stable cell 
lines. 
Western blot for detection of full-length Rheb2 protein 
NIH-3T3 Mieg3 and Rheb2-Mieg3 cellular lysates were harvested by resuspension of 
cells in SDS-lysis buffer followed by sonication twice for 3 minutes at 0°C and boiling at 
95°C for 5 minutes, and underwent SDS-polyacrylamide gel electrophoresis using tris-
glycine (TG) gels (Invitrogen). Proteins were transferred to PVDF membranes and 
blotted with anti-Flag antibody (Sigma). Cellular lysates from BaF3 and 32D Mieg3 or 
Rheb2-Mieg3 cells were harvested in M-PER buffer (Pierce, Rockford IL, USA) 
containing 1:100 dilutions of protease and phosphatase inhibitors (Calbiochem, 
Darmstadt Germany) according to manufacturer’s protocol and were blotted with an anti-
Rheb2 antibody (Abnova, Taipei, Taiwan). 
For shRNA knock-down of Rheb2 protein, pSUPER.Retro.GFP vectors (Oligoengine, 
Seattle WA, USA) containing specific anti-Rheb2 DNA sequence encoding an shRNA 
molecule were obtained from Dr. Lawrence Quilliam’s laboratory. The specific anti-
Rheb2 sequence from this vector as well as a scrambled shRNA sequence were cloned 
into the retroviral vector pSIREN.RetroQ-ZsGreen (Clontech) by ligation of annealed 
primers containing the shRNA coding sequence using DNA ligase (Invitrogen). Accurate 
cloning of these vectors was confirmed by DNA sequencing (IUSM DNA sequencing 
core facility). The scrambled and specific anti-Rheb2 vectors were transfected into 
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parental and Rheb2-overexpressing 32D cells using nucleofection (Amaxa, Gaithersburg 
MD, USA) according to the manufacturer’s protocol. Cell protein lysates were harvested 
using M-PER (Pierce) 24 hours after transfection. The percent GFP+ cells in parental 
32D samples was used to estimate the transfection efficiency. Lysates were blotted with 
anti-Rheb2 antibody (Abnova) to determine the extent of shRNA knock-down of Rheb2 
protein.  
Primary mouse BM cell transduction 
For all primary mouse hematopoietic cell experiments, mouse bone marrow (mBM) was 
isolated from femurs of wild-type C57/Bl6 mice using aseptic procedures. BM cells were 
resuspended in αMEM medium and layered on top of a lympholyte M gradient 
(Cedarlane, Burlington NC, USA) according to manufacturer’s protocol in order to 
separate MNCs. mBM MNCs were prestimulated for 48 hours at 37°C in αMEM medium 
containing 20% FBS and the following growth factors each at 100 ng/ml each: mouse 
stem cell factor, human thrombopoietin and human Flt3 ligand (SFT) (Biovision, 
Mountain View CA, USA). The prestimulated cells were resuspended in either Mieg3 or 
Rheb2-Mieg3 supernatants containing SFT (100 ng/ml) and plated on 8 µg/cm2 
retronectin (Takara, Shiga Japan) coated 6-well plates pre-loaded with retroviral 
supernatants as described previously (Tao et al. 2004). After a 4.5 hour incubation, the 
supernatants were replaced with fresh αMEM + SFT (100 ng/ml). Transductions were 
repeated the next day. To isolate GFP+ cells, cells were Fluorescence Activated Cell 
Sorter (FACS) separated on the following day (total of 4 days after isolating from the 
mice).  
 
 
32 
 
Mouse Myeloid Colony Assays 
mBM MNCs were transduced and GFP+ cells were sorted FACS. The cells were 
resuspended in IMDM after sorting and plated at various cell concentrations in semi-
solid methylcellulose colony assays. These assays have been previously described 
(Broxmeyer et al. 2003a; Broxmeyer et al. 2003b). Briefly, GFP+ cells were plated in 1% 
methylcellulose containing 30% FBS (Hyclone), 0.1 mM Hemin, 5% pokeweed mitogen 
spleen conditioned medium (PWMSCM), 1U/ml Erythropoietin (Amgen, Thousand Oaks, 
CA USA) and 50 ng/ml mouse Stem cell factor (muSCF). Colonies were scored after 6-8 
day incubation in a low oxygen tension (5% CO2, 5% O2), humidified incubator. For 
expansion cultures, GFP+ cells were plated in complete medium containing SFT (50 
ng/ml each); cells were removed from the liquid cultures at 0, 48 hours and 1 week and 
plated in methylcellulose colony assays. For delayed growth factor colony assays, GFP+ 
cells were plated in methylcellulose containing FBS with or without 100 ng/ml human 
SDF-1/CXCL12 (Biovision), but without other growth factors. The combination of hemin, 
PWMSCM, EPO and muSCF was added to the plates at 0, 24 and 48 hours after 
plating.   
Delayed Growth-factor addition proliferation of mouse hematopoietic cell lines and 
Western Blot for mTOR activity 
For delayed IL-3 proliferation assays, 32D or BaF3 cells were washed twice to remove 
residual IL-3 from the cultures and plated at 1x105 cells per ml in 24-well culture plates. 
The cells were starved of IL-3 at 37°C for 8 or 12 hou rs after which IL-3 was added to 
the individual wells at various concentrations. The cells were counted by trypan blue 
exclusion after expansion. To determine mTOR activity, 32D or BaF3 cells were starved 
of IL-3 for 8 or 12 hours, after which PBS (Control) or IL-3 (10 ng/ml or 0.25 ng/ml) was 
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added for 20 or 40 minutes, cells were washed once with PBS, and cell protein lysates 
were harvested using M-PER lysis buffer (Pierce) containing 1:100 dilutions of 
phosphatase and protease inhibitors (Calbiochem, Darmstadt, Germany) according to 
manufacturer protocols. Proteins were separated by SDS-polyacrylamide gel 
electrophoresis using TG gels (Invitrogen) and blotted with anti-phosphorylated 
ribosomal S6 antibody (Ser235/236, Cell Signaling Technology, Danvers MA, USA). 
Anti-Beta actin or anti-total ribosomal S6 protein (Cell Signaling Technology) were used 
as loading controls (Sigma, St. Louis MO, USA). 
In vitro expansion of KSL cells 
Transduced unsorted mouse BM MNCs were cultured in IMDM + 10% FBS + SFT (50 
ng/ml) beginning on the fourth day after isolation from C57/Bl6 mice. The cells plated in 
duplicate wells at approximately 2 x 106 cells per well. Additionally, either 50 nM 
rapamycin (Cell Signaling Technologies) or vehicle control (methanol) was added to the 
duplicate cultures at this time. The cells were incubated for 4 days at 37°C and all wells 
were split 1:1 with fresh medium containing SFT containing either methanol or 
rapamycin once during this 4 day culture. On the fourth day of culture, cells were 
harvested and resuspended in complete IMDM without growth factors. The DNA binding 
dye Hoechst 33342 (Invitrogen) was added to the cells to give a final concentration of  
1µg/ml and incubated at 37°C for 30 minutes. After 30 m inutes, the cells were 
resuspended in complete IMDM containing anti-c-kit PE, anti-sca-1 PeCy5.5 and anti-
lineage APC antibodies (BD) or isotype control antibodies (BD) and incubated at 4°C for 
20 minutes. The cells were washed once with complete IMDM, resuspended in complete 
IMDM and analyzed by FACS.  
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In vivo homing and Competitive Repopulation Transplants 
For in vivo short-term homing, 1x106 transduced unsorted mBM MNCs from C57/Bl6 
(CD45.2+) mice were injected by tail-vein into lethally-irradiated recipient BoyJ (CD45.1+) 
mice. BM from bilateral femurs was harvested after 24 hours and analyzed by FACS for 
CD45.1-PE and CD45.2-APC markers (BD).  
Competitive repopulation assays were performed as previously described (Broxmeyer et 
al. 2005). For short-term repopulation, 4x105 transduced unsorted mBM MNCs from 
C57/Bl6 mice (CD45.2+) were mixed with 4x105 BoyJ (CD45.1+) BM cells and injected by 
tail-vein into C57/Bl6/BoyJ F1 double positive recipients (CD45.1+, CD45.2+) which had 
been total body irradiated with 9.5 Gray (950 Rad). At 1, 2 and 4 weeks after 
transplantation, peripheral blood was harvested by tail-vein bleeding into heparinized 
microcapillary tubes (Fisher Scientific, Pittsburg PA, USA), RBCs were lysed by 
incubating with 2.5 mls of RBC lysis buffer (0.155 M NH4Cl, 0.01 M KHCO3, 0.1 mM 
EDTA in H2O and filter sterilized), washed once with PBS + 2% BSA and resuspended in 
staining buffer containing 1:10 dilution of Fc receptor blocking agents (either mouse 
gamma globulin, Jackson Immunoresearch or mouse Fc receptor blocker, Miltenyi 
Biotec). PB cells were then stained with anti-CD45.2 APC and anti-CD45.1 PE 
antibodies (BD) or isotype control antibodies (BD) for FACS analysis. PB from BoyJ and 
C57/Bl6 animals were used as controls. BM cells were aseptically harvested at 1, 2 and 
4 weeks after transplantation, resuspended in SB containing Fc receptor blocking agents 
and stained with anti-CD45.1-PE and anti-CD45.2-APC (BD) antibodies or isotype 
control antibodies (BD) for FACS analysis. BM was further stained with anti-CD117-PE 
(c-kit), anti-Ly-6A/E-Pe-Cy5.5 (Sca1) and anti-Lineage-APC (Lin) antigens (BD and 
Caltag, Carlsbad CA, USA) or the corresponding isotype control antibodies (BD and 
Caltag) for FACS analysis. Absolute numbers of GFP+LS cells were calculated by taking 
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the number of GFP+LS events divided by the total number of gated events multiplied by 
the total number of BM mononuclear cells isolated from both femurs and tibia from each 
recipient counted using a Coulter counter. 
For Long-term competitive repopulation, either 4x105 (1:1 group) or 1.6x105 (0.4:1 
group) transduced mBM MNCs from C57/Bl6 (CD45.2+) mice were mixed with 4x105 BM 
cells from BoyJ (CD45.1+) mice; these cells were injected into irradiated recipient BoyJ 
(CD45.1+) mice. PB was harvested at 1, 2.5, 3.5 and 5 months after transplantation and 
stained with anti-CD45.2 APC and anti-CD45.1 PE antibodies (BD) or isotype control 
antibodies (BD) as described above.  
Secondary non-competitive transplantation 
BM cells were harvested from primary BoyJ transplant recipients at 5 months after 
transplantation, resuspended in PBS and injected by tail-vein into secondary BoyJ mice 
irradiated with 9.5 Gray TBI. 2 x106 cells from each primary animal were transplanted 
into each of four recipient secondary animals. PB was harvested from the secondary 
animals at 1 and 2 months after transplantation and analyzed for CD45.1 and CD45.2 
chimerism as explained above.  
Multilineage differentiation by FACS staining 
PB cells from 1 month primary competitive transplant recipient BoyJ animals were 
resuspended in SB containing Fc receptor blocking agent and stained with anti-CD11b 
APC, anti-CD3 APC, anti-GR-1 PE and anti-B220 PeCy7 (BD) antibodies and analyzed 
by FACS.  
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Analysis of data and statistical analysis 
Flow data were analyzed using either WinMDI (The Scripps Research Institute, La Jolla 
CA, USA) or FCS Express V3 software (De Novo Software, Ontario, Canada). Statistical 
tests were performed using Student’s t-test with p<0.05 significance cut-off. 
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RESULTS 
Part 1: Inhibition of the surface peptidase CD26/DPPIV enhanced hUCB CD34+ in vivo 
engraftment of immunodeficient NOD/SCID mice 
CD26 was preferentially expressed by immature CD34+CD38- hUCB cells 
Our laboratory established a role for CD26/DPPIV in modulation of mouse HSC 
engraftment in vivo (Christopherson et al. 2004). This current study sought to expand on 
these results by examining whether CD26/DPPIV could modulate in vivo engraftment of 
human UCB CD34+ cells, a population purified for HSCs and HPCs, using a xenogeneic 
NOD/SCID mouse transplantation model. First, we determined CD26/DPPIV expression, 
using FACS, in subsets of the CD34+ population. The CD34+CD38- population is 
enriched for HSCs compared to the CD34+CD38+ population; therefore, we compared 
CD26 expression in these two subsets. Approximately 10% of CD34+ cells are CD38-. 12 
% ± 2.6 S.D. of CD34+CD38- hUCB cells expressed CD26/DPPIV, compared to 5 % ± 
2.2 S.D. of CD34+CD38+ cells, a significant difference (Figure 1, p<0.01), suggesting 
preferential expression in immature cells. These data are similar to mouse BM cell data, 
showing a very high percentage of phenotypic HSCs express CD26/DPPIV 
(Christopherson et al. 2003).  
Pre-treatment of hUCB CD34+ cells with the CD26/DPPIV inhibitor Diprotin A enhanced 
their engraftment of NOD/SCID mice 
The NOD/SCID xenogeneic immunodeficient mouse model is used to analyze human 
hematopoietic cell engraftment in vivo (Bhatia et al. 1997b). This mouse model is an 
improvement over previous immunodeficient strains such as SCID in that the level of 
human cell engraftment able to be attained is higher due to decreased immune cell 
function (Lapidot et al. 1997). Diprotin A is an inhibitor of CD26/DPPIV used in  
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Figure 1: Expression of CD26 in CD34+ subsets. CD34+ cells were isolated from CB 
using magnetic cell sorting and were stained with anti-human CD34, CD38 and CD26 
antibodies. A: Representative histograms are shown for one CB unit. The shaded line is 
isotype control staining, while the open line is the anti-CD26 staining. B: The graph 
shows pooled data from five separate CB units analyzed.  
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previous experiments to inhibit the peptidase activity (Christopherson et al. 2004). Initial 
experiments were performed to determine the effect of Diprotin A on the engraftment of 
human CD34+ CB cells in sub-lethally (300 Rad) irradiated NOD/SCID mice. We used a 
short-term (15 minutes) pretreatment of cells with either 5 mM Diprotin A or PBS before 
injecting cells into recipient animals. After 6 weeks, human cell engraftment was 
assessed by measuring human CD45 positive cells in recipient marrow. The engraftment 
of human cells in these transplanted NOD/SCID animals was easily detected using anti-
human CD45 antibodies by FACS analysis without significant background staining from 
non-transplanted mice (Figure 2). Figures 3 and 4 show results of two independent 
transplant experiments using highly purified (>90%) CD34+ cells from hUCB. 
Pretreatment of the cells with Diprotin A significantly enhanced engraftment of human 
cells in both experiments. The effect of Diprotin A was most pronounced when control 
cell engraftment was relatively low (<15%). When control cell engraftment was relatively 
high (80,000 cell group in Figure 4), Diprotin A did not significantly enhance engraftment. 
Diprotin A did not negatively affect engraftment, even when control cell engraftment was 
relatively high (Figure 4).  Figure 5 shows another independent transplant experiment 
using CD34+ cells that were less pure (<40% CD34+). Under these conditions, Diprotin A 
pretreatment again significantly enhanced engraftment of human CD45+ cells. This 
condition of a relatively less pure CD34+ cell sample may better reflect clinical CB 
transplantation, since not all clinical transplants are performed with pure HSC/HPC 
populations. 
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Figure 2: Analysis of NOD/SCID mice for human hematopoietic cell engraftment. 
Shown are representative FACS plots illustrating no non-specific staining of NOD/SCID 
recipient mouse BM cells using the anti-human CD45 antibody (top), no non-specific 
staining of transplanted NOD/SCID mice using the isotype control antibody (middle), and 
specific detection of human cells in transplanted NOD/SCID mice using the anti-human 
CD45 antibody (bottom). Note: Fewer events are shown for the SSC-H versus FSC-H 
plots on the left side in order to accurately gate out sub cellular debris from the analysis. 
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Figure 3: CD26 inhibition enhanced NOD/SCID engraftment. Purified CD34+ cells 
were treated with either PBS (control) or 5 mM Diprotin A for 15 minutes at 37°C before 
injecting by tail vein into sublethally irradiated NOD/SCID mice (8 x 104 cells per animal). 
Bone marrow was isolated from 7 control and 6 Diprotin A animals 6 weeks after 
transplantation.  
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Figure 4: CD26 inhibition enhanced NOD/SCID engraftment. Purified CD34+ cells 
were treated with either PBS (control) or 5 mM Diprotin A for 15 minutes at 37°C before 
injecting by tail vein into sub lethally irradiated NOD/SCID mice at either 4 x 104 or 8 x 
104 cells per animal. Bone marrow was isolated from five animals in all four groups about 
8 weeks after transplantation. 
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Figure 5: CD26 inhibition enhanced NOD/SCID engraftment of <40% pure CD34+ 
cells. NOD/SCID animals were transplanted with various numbers of CD34+ cells  (2 x 
104, 4 x 104, or 8 x 104) which had been pre-treated with either PBS or 5 mM Diprotin A 
for 15 minutes at 37°C.  Bone marrow was isolated fro m 18 animals in each group about 
9 weeks after transplantation. Results of animals were pooled into two groups (Control 
vs. Diprotin A) because there was no dose response in engraftment due to number of 
cells transplanted. 
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CD26 pre-treatment did not affect multilineage differentiation of transplanted CD34+ 
hUCB cells 
Any treatment or strategy which affects the engraftment of hematopoietic cells has to be 
analyzed for its role in affecting differentiation of the transplanted cells. For any 
treatment to be clinically effective, the transplanted cells must be able to differentiate into 
all lineages of the blood normally, otherwise the recipient could have serious 
complications and morbidity. To determine if CD26 inhibition impaired or skewed 
differentiation of transplanted human CD34+ cells in the NOD/SCID mouse recipients, 
we analyzed the expression of various surface markers associated with primarily the 
myeloid and B lymphoid lineages, as well as markers for immature HSC populations. 
Transplanted mouse bone marrow cells were stained and analyzed by FACS for their  
expression of human CD34, CD38, CD19 and CD33, markers routinely used to 
determine multi-lineage potential of engrafted human cells in NOD/SCID mice (Bhatia et 
al. 1997b; Ishikawa et al. 2003). CD34 is a marker for human HSCs and HPCs (Janeway 
2005). CD38 is used in conjunction with CD34 to delineate mature versus immature 
stem/progenitor populations (Ishikawa et al. 2003; Janeway 2005). CD19 is a B-cell 
marker (Janeway 2005) and CD33 is a myeloid cell marker (Janeway 2005). Figure 6 
shows representative FACS plots from animals transplanted with control and Diprotin A 
treated cells demonstrating multi-lineage staining of the human cells. When mice 
exhibiting human chimerism greater than 20% were analyzed and the data pooled, no 
significant differences were noted in percentages of the various populations assayed 
(Table 1), suggesting that CD26 inhibition did not significantly affect lineage 
differentiation of the transplanted CD34+ cells.   
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Figure 6: Effect of CD26 inhibition on multilineage differentiation of CD34+ 
transplanted cells. These FACS plots show representative NOD/SCID animals from the 
experiment in Figure 4. Gated human (CD45+) cells are shown expressing CD34, CD38, 
CD19 and CD33 surface markers.  
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% CD38+CD34- % CD38+CD34+ % CD34+CD38-
Control 68.4 ± 2.4 20.7 ± 3.8 0.25 ± 0.27
Diprotin A 68.6 ± 10.9 21.8 ± 10.0 0.17 ± 0.18
% CD33+ % CD19+
Control 11.5 ± 8.5 64.5 ± 13.6
Diprotin A 5.7 ± 3.3 73.5 ± 7.5
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Table 2: Phenotype of engrafted human cells in NOD/SCID mice. CD26 inhibition did 
not impair multilineage differentiation of transplanted CD34+ cells. Table 2 shows data 
pooled from animals which had chimerism of greater than 20% (N=5 control and N=8 
Diprotin A). The percentages shown are within the CD45+ human population (Mean ± 
SD). There were no significant differences in any of the populations. 
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Part II: Overexpression of the novel Ras molecule, Rheb2, enhanced HPC and HSC 
growth and impaired HSC in vivo repopulating activity. 
Understanding which signaling molecules and pathways affect hematopoietic cell 
proliferation, self-renewal, differentiation and engraftment is important for clinical uses of 
these cells, including ex vivo expansion, viral transduction to correct genetic deficiencies 
and immune cell manipulation to control GVHD.  
We were interested in the role of the novel ras molecule, Rheb2, in mouse 
hematopoietic cell function for two reasons: its expression pattern in mouse HSCs 
suggests it may be important for their function, and it activates the mTOR pathway, 
known to be involved in regulating hematopoietic cell growth, survival and other 
functions. We studied the role of Rheb2 in mouse hematopoietic cells by overexpressing 
it using the retroviral vector, Mieg3. The Mieg3 vector contains an enhanced GFP 
marker protein which allows for easy detection of transduced cells in various cell types. 
FACS analysis of transduced cells, including 3T3 and mouse primary BM cells, shown in 
Figure 7 illustrates that positively transduced cells can be separated easily from the non-
transduced population.  
We confirmed that the Rheb2-MIEG3 vector produced full-length recombinant Rheb2 
protein by Western blotting cellular lysates with both anti-Flag and anti-Rheb2 antibodies 
in various cell lines, as shown in Figure 8. To further confirm the specificity of the band 
seen in the Western blots, we used an shRNA vector containing a sequence specific 
against Rheb2 cDNA and, using transient transfection, were able to knock-down the 
expression of the recombinant Rheb2 in cells overexpressing it as shown in Figure 9. 
These results confirmed that full-length Rheb2 was produced by the retroviral vector 
Rheb2-Mieg3. 
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Figure 7: Detection of GFP+ cells after transduction with Mieg3 and Rheb2-Mieg3 
retroviral vectors. Mieg3 or Rheb2-Mieg3 retroviral supernatants were used to 
transduce primary mouse MNCs or 3T3 cells and GFP+ cells were determined by FACS. 
Shown are representative FACS plots illustrating that both retrovirus transduce cells 
equally well leading to GFP expression which can be easily differentiated using FACS 
analysis.  
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Figure 8: Production of Rheb2 protein by transduction with the Rheb2-Mieg3 
retrovirus. Mieg3 and Rheb2-Mieg3 retroviral supernatants were used to transduce 
NIH-3T3 (A) and BaF3 (B) cells; lysates were collected and production of full-length 
(about 20kD) Rheb2 protein was confirmed in cells transduced with the Rheb2-Mieg3 
virus by blotting for Flag tag in A and anti-Rheb2 (Abnova) in B. Part B shows 3 samples 
per transduced BaF3 cell lines. 
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Figure 9: Effect of shRNA knock-down in cells overexpressing Rheb2. Transduced 
32D cells overexpressing Rheb2 protein (labeled as Rheb2 32D) were transfected with 
plasmid DNA vectors encoding scrambled or specific Rheb2 shRNA constructs, and 
protein lysates were analyzed for Rheb2 protein by Western Blot. The sequence of 
Rheb2 used to design the shRNA vectors is shown in the gray box above. The 
scrambled vector had no ability to knock-down Rheb2 protein compared to a negative 
control transfected without DNA. The specific anti-Rheb2 vector was able to partially 
silence the expression of Rheb2 in these cells. Transfection efficiency in these 
experiments varied between 40 and 60%. Representative of more than 3 independent 
experiments. 
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Overexpression of Rheb2 enhanced proliferation and mTOR signaling in two mouse 
hematopoietic progenitor cell lines 
To test the ability of overexpressed Rheb2 protein to activate the mTOR pathway, we 
created stable, transduced mouse BaF3 and 32D cell lines by transduction with Mieg3 
and Rheb2-Mieg3 viruses and FACS sorting followed by expansion. BaF3 is a mouse 
pro B-cell line, and 32D is a mouse myeloid progenitor cell line. Both of these are 
dependent on the growth factor IL-3 for growth and survival. In BaF3 cells, signaling 
through the mTOR pathway is important for mediating IL-3-induced growth (Cruz et al. 
2005). Therefore, we tested the ability of Rheb2 to enhance proliferation and mTOR 
signaling in response to delayed addition of IL-3.  
32D cells were plated in the absence of IL-3 and incubated for 8 hours before IL-3 was 
added back to the cultures. Illustrated in Figure 10A, 32D cells overexpressing Rheb2 
proliferated significantly greater than empty vector transduced cells in response to 
delayed IL-3 addition. This enhancement of proliferation was significant at three different 
concentrations of IL-3 added back to the cultures. In addition to the proliferation of 32D 
cells, signaling through the mTOR pathway was measured after delayed IL-3 addition by 
Western blotting for phosphorylated S6 ribosomal protein, a known downstream effector 
of mTOR commonly used to measure its activity and inhibited by rapamycin treatment 
(Raslova et al. 2006). As shown in Figure 10B, 32D cells overexpressing Rheb2 had 
hyperactive mTOR activity in response to IL-3 addition compared to empty vector cells. 
This hyperactive mTOR signaling was evident at 20 and 40 minutes after IL-3 addition.  
BaF3 cells were transduced and analyzed in a similar fashion as 32D cells. In response 
to 12 hour IL-3 starvation followed by IL-3 addition, Rheb2-BaF3 cells proliferated 
significantly greater than Mieg3-32D cells as shown in Figure 11A. When measuring 
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mTOR activity after starvation and IL-3 addition, Rheb2-BaF3 had increased signaling 
through this pathway as seen in Figure 11B. 
These results demonstrate that Rheb2 overexpression increased the proliferation in 
response to delayed IL-3 addition of two hematopoietic progenitor cell lines, 32D and 
BaF3. Correlated with the increased proliferation, Rheb2 overexpression increased 
signaling through the mTOR pathway, confirming that Rheb2 can activate this pathway.  
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Figure 10: Effect of Rheb2 overexpression on 32D proliferation and mTOR 
signaling. 32D cells were transduced with Mieg3 or Rheb2-Mieg3 retroviral 
supernatants, GFP+ cells FACS sorted and expanded to create stably expressing cell 
lines. In part A, cells were plated in triplicate at 1 x 105 cells per well without IL-3 and 
starved for 8 hours. After 8 hours, IL-3 (10 ng/ml, 0.1 ng/ml or 0.01 ng/ml) was added 
back to the cultures and viable cell counts were taken after 48 hours in culture by trypan 
blue exclusion counting. Combined data from 2 independent experiments (mean ± SD). 
** p<0.01. For part B, 32D cells were plated at 1 x 106 cells per well, starved without IL-3 
for 8 hours. After 8 hours, IL-3 (10ng/ml) was added to the wells for 20 or 40 minutes. 
Negative controls had PBS added for 40 minutes. Cellular lysates were taken and 
Western blots were performed for phosphorylated ribosomal S6 protein levels. 
Representative of two independent experiments. Part C shows levels of total ribosomal 
S6 protein in representative 32D samples indicating that total S6 was not increased in 
the Rheb2 cell line. 
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Figure 11: Effect of Rheb2 overexpression on BaF3 cell proliferation and mTOR 
signaling. BaF3 cells were transduced with Mieg3 or Rheb2-Mieg3 retroviral 
supernatants, GFP+ cells FACS sorted and expanded to create stably expressing cell 
lines. In part A, cells were plated in triplicate at 1 x 105 cells per well without IL-3 and 
starved for 12 hours. After 12 hours, IL-3 (0.25 ng/ml, 0.025 ng/ml or 0.0025 ng/ml) was 
added back to the cultures and viable cell counts were taken after at least 33 hours in 
culture by trypan blue exclusion counting. Combined data from 3 independent 
experiments (mean ± SD). * p<0.05. For part B, BaF3 cells were plated at 1 x106 cells 
per well, starved without IL-3 for 12 hours. After 12 hours, IL-3 (10ng/ml) was added to 
the wells for 20 or 40 minutes. Negative controls had PBS added for 40 minutes. Cellular 
lysates were taken and Western blots were performed for phosphorylated ribosomal S6 
protein levels. In addition to 12 hour starvation, hyperactivation of mTOR pathway was 
observed after 8 hour IL-3 starvation.  
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Overexpression of Rheb2 enhanced colony-forming ability of primary mouse 
hematopoietic progenitor cells 
To determine the effect of overexpressing Rheb2 on the colony-forming ability of 
hematopoietic cells, primary mouse BM cells were transduced with Mieg3 and Rheb2-
Mieg3 vectors, GFP+ cells sorted by FACS and plated in semi-solid methylcellulose 
colony assays containing growth factors conducive for progenitor cell growth including 
PWMSCM, hemin, FBS and SCF (see Materials and Methods for further explanation). 
CFU-GM, BFU-E and CFU-GEMM colonies were counted after 6-8 days incubation. 
Overexpression of Rheb2 in these cells significantly increased the colony-forming ability 
compared to vector control cells as illustrated in Figure 12. Average numbers of CFU-
GM colonies per 4000 cells plated significantly increased from 44 ± 3.6 SEM in Mieg3 
plates to 85 ± 10.6 SEM in Rheb2 plates. The average number of CFU-GEMM increased 
from 1.8 ± 0.5 SEM in Mieg3 plates to 5.4 ± 1.5 SEM in Rheb2 plates. In addition to 
these two colony types, the average number of Bfu-E colonies per 4000 cells increased 
due to Rheb2 overexpression; however, the numbers were very low and did not attain 
statistical significance. 
In addition to plating GFP+ cells directly in colony assays after FACS sorting, we cultured 
these cells up to one week after sorting in liquid culture containing SFT (50 ng/ml each) 
growth factors. Cells were removed from the liquid cultures at 48 hours and 1 week after 
seeding and plated in methylcellulose colony assays. Figure 13 shows in part A the 
expansion of the total number of GFP+ cells determined by trypan blue exclusion 
counting and in part B the expansion of CFU-GM progenitors as determined by 
methylcellulose colony assays. The numbers of total GFP+ cells were significantly 
increased up to two-fold over Mieg3 cells by Rheb2 overexpression as shown in Figure 
13A. Consistent with an expansion of total cells, Rheb2 overexpression expanded 
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colony-forming CFU-GM progenitors greater than 2-fold over Mieg3 progenitor numbers 
at 48 hours and 1 week after plating in liquid culture. These results demonstrate that 
overexpression of Rheb2 can expand total cell numbers as well as progenitor cell 
numbers in liquid cultures. 
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Figure 12: Effect of Rheb2 overexpression on primary mBM MNC colony 
formation. Mouse BM MNCs were transduced with either Mieg3 or Rheb2-Mieg3 
retroviral supernatants. GFP+ cells were FACS sorted and plated in triplicate in 
methylcellulose colony assays containing PWMSCM, FBS, hemin and SCF (50 ng/ml) 
and colony numbers scored after 6-7 days incubation at low oxygen tension (O2 = 5%). 
Results are combined for three independent experiments (mean ± SEM). * p<0.05 
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Figure 13: Effect of Rheb2 overexpression on colony-forming cell expansion in 
vitro. GFP+ cells (5 x 104 per well) were cultured in triplicate in medium containing SFT 
(50 ng/ml each) for the indicated times. At each time point, total viable cell numbers 
were measured by trypan blue exclusion counting (part A), and cells were removed from 
the liquid cultures and plated in triplicate in methylcellulose colony assays. Numbers of 
CFU-GM progenitors per well were calculated by numbers of progenitors per input cells 
in methylcellulose assays (part B). Mean ± SD. * p<0.05. 
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Rheb2 overexpression enhanced the survival of primary hematopoietic progenitors in 
delayed growth factor addition colony assays 
The mTOR pathway, downstream of Rheb2, is a positive regulator of cell survival of 
various cell types under disparate stimuli. Therefore, we tested the ability of 
overexpressed Rheb2 to enhance the survival of primary hematopoietic progenitor cells 
using a delayed growth factor colony assay system. Primary mouse MNCs were 
transduced and FACS sorted. The GFP+ cells were plated in methylcellulose colony 
assays in the absence of colony-stimulating growth factors as described in Materials and 
Methods. At 0, 24 and 48 hours after plating, growth factors were added to individual 
plates. Colonies were scored after 6-8 days of incubation. In addition, we tested the 
ability of CXCL12/SDF-1, a known pro-survival chemokine, to enhance the colony 
formation of these transduced cells by adding the chemokine or PBS to the plates at 
time 0.  
The results from these delayed growth factor addition assays are shown in Figure 14. In 
the absence of CXCL12/SDF-1, overexpression of Rheb2 significantly enhanced, 
compared to empty vector, progenitor survival when standardized to time 0 CFU-GM 
colony numbers (Figure 14). In the presence of CXCL12/SDF-1, the survival of Mieg3 
progenitor cells was enhanced as expected; however, the survival of Rheb2 
overexpressing cells was not enhanced as shown in Figure 14. These results suggest 
that Rheb2 enhances the survival of progenitor cells, and that this effect is not increased 
by CXCL12/SDF-1 stimulation.  
There are many possible explanations for the lack of enhancement of Rheb2 transduced 
cell survival by SDF-1. The survival of these cells may already be maximally stimulated 
by Rheb2 overexpression and introducing additional survival factors may be masked by 
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its effect. In addition, Rheb2 transduced cells may have downregulated the SDF-1 
receptor CXCR4, thus preventing the cells from responding to SDF-1. An interesting 
possibility is that both SDF-1 and Rheb2 stimulate common intracellular pathways 
leading to enhanced survival. Specifically, both SDF-1 and Rheb2 may stimulate the 
mTOR pathway. We tested this hypothesis by stimulating cultured mouse MNCs after a 
period of starvation with various concentrations of CXCL12/SDF-1, isolating cellular 
lysates and Western blotting for mTOR activity using anti-phospho S6 ribosomal protein, 
a known downstream effector of mTOR commonly used to measure mTOR activity and 
inhibited by rapamycin treatment (Raslova et al. 2006). We found that indeed SDF-1 
activated the mTOR activity when compared to unstimulated cells (Figure 15). This 
suggests that Rheb2 and SDF-1 may share downstream effectors leading to enhanced 
cell survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
0 hr.                        24 hr.                        48 hr.
%
 
C
FU
-
G
M
 
c
o
lo
n
ie
s
 
re
m
a
in
in
g 
(c
o
m
pa
re
d 
to
 
tim
e
 
0)
SDF-1/CXCL12 100 ng/ml - +
Mieg3 no SDF-1
Rheb2 no SDF-1
Rheb2 + SDF-1
Mieg3  + SDF-1
p<0.05
p<0.05
- + - +
76 
 
Figure 14: Rheb2 overexpression enhanced progenitor survival. Mouse BM MNCs 
were transduced and FACS sorted for GFP+ cells. GFP+ cells were plated in 
methylcellulose colony assays absent of the growth factors hemin, PWMSCM and SCF. 
At the indicated time points, these GFs were added to the methylcellulose plates. Colony 
assays were incubated a total of 6-7 days and colonies counted. The percent remaining 
at each time point was calculated by standardizing to the number of colonies at time 0 in 
both Mieg3 and Rheb2-Mieg3 assays. Representative of two independent experiments 
(mean ± SD).  
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Figure 15: Effect of SDF-1/CXCL12 stimulation on mTOR activity in mBM MNCs. 
MNCs were cultured in medium containing SFT (50 ng/ml each) for 48 hours. Cells were 
starved of SFT for 8 hours and stimulated with either PBS (negative control), SFT (50 
ng/ml each, positive control) or various concentrations of SDF-1/CXCL12 as indicated 
for 40 minutes. Cellular lysates were harvested and Western blots were performed to 
measure the level of phosphorylated ribosomal S6 protein. Beta actin was used as a 
loading control. Representative of two independent experiments. 
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Overexpression of Rheb2 expanded phenotypic HSCs in vitro – a process partially 
dependent upon mTOR signaling 
We have shown thus far that overexpression of Rheb2 had positive effects on growth 
and survival of transduced mouse hematopoietic progenitor cells. To further define the 
role of Rheb2 on immature HSC populations, we transduced mouse MNCs and cultured 
them in vitro in the combination of SFT (50 ng/ml each) for 4 days after transduction. 
After 4 days, we determined the percentage of phenotypic hematopoietic stem cells, 
defined as c-kit+, sca-1+ and lineage- (KSL) in the cultures. In addition, we cultured the 
cells in the absence or presence of rapamycin (50 nM) to determine if mTOR inhibition 
could help to reverse the expansion of the HSCs. The results of these experiments are 
shown in Figure 16. In 16A, representative FACS plots of cultured cells clearly show an 
increased percentage of Rheb2 GFP+ (transduced) cells within the total KSL population 
compared to Mieg3 GFP+ cells. Importantly the percent of total GFP+ cells (25% for 
Mieg3 and 23% for Rheb2), as well as total cell numbers were similar in Mieg3 and 
Rheb2 cultures, suggesting a specific effect of Rheb2 overexpression on immature KSL 
cells. The graph in Figure 16B shows tabulated data on expansion of KSL cells. 
Overexpression of Rheb2 significantly expanded the percent of GFP+KSL cells four-fold 
over empty vector transduced cells. Importantly, the percent of GFP-KSL cells was not 
significantly affected by Rheb2 overexpression, illustrating that these results are not due 
to general KSL expansion but are specific for the GFP+ transduced fraction. In addition, 
the percent of GFP+KSL cells in both Mieg3 and Rheb2 cultures shortly after 
transduction (less than 1 day) were not dramatically different (0.08% in Mieg3 and 
0.12% in Rheb2 cultures), suggesting that the Rheb2 retrovirus was not simply targeting 
immature cells preferentially during the transduction period.   
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The addition of rapamycin to these cultures decreased the percentage of KSL cells in 
both the GFP- and GFP+ fractions in both Mieg3 and Rheb2 cultures. This decrease was 
significant for Rheb2 GFP+ cells but did not reach significance for Mieg3 GFP+ cells. 
Rapamycin did not completely reverse the expansion of KSL cells due to Rheb2, and 
there was still a significant increase in GFP+KSL percentage in Rheb2 versus Mieg3 
cultures. This suggests that either the concentration of rapamycin was not high enough 
at 50 nM or that the mechanism controlling this expansion is mediated by mTOR as well 
as other cellular pathways. Additionally, the use of rapamycin in the context of 
constitutive Rheb2 activity (overexpression) may release autoinhibitory feedback loops 
known to be downstream of mTOR acting on Akt signaling (explained further in 
Discussion). Overall, these results show that Rheb2 can expand KSL cells in vitro which 
can be partially inhibited by blocking mTOR activity. 
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Figure 16: Rheb2 overexpression expanded immature hematopoietic cells in vitro. 
Mouse BM MNCs were transduced and cultured in medium containing SFT (50 ng/ml) 
with either rapamycin (50 nM) or vehicle control (methanol) in duplicate for each 
condition for 4 days after transduction (total of 8 days after isolation from mice). The 
percentage of KSL cells out of the total population was determined in GFP+ (transduced) 
and GFP- (non-transduced) populations. Representative FACS plots shown in part A, 
note the percentage in the middle plots refer to the percentage of KSL cells out of the 
lineage negative population. Combined results from two independent experiments (mean 
± SEM) are shown in part B. p values are shown on the graph. 
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Overexpression of Rheb2 enhanced the cell cycling status of mouse KSL cells expanded 
in liquid culture 
To test whether the expansion of KSL cells due to Rheb2 overexpression accompanied 
an increase in the cycling of the KSL cells, we used Hoescht 33342 DNA staining to 
determine the percent of KSL cells in G1 versus S/G2/M in vitro. 
In in vitro expanded cultures, Rheb2 transduced GFP+ KSL cells had a significantly 
greater percentage of cells in S/G2/M compared to Mieg3 GFP+KSL cells (Figures 17 
and 18). In Figure 18, two independent experiments analyzing the percentage of cycling 
S/G2/M cells in Mieg3 and Rheb2 GFP- and GFP+ fractions cultured in the absence or 
presence of 50 nM rapamycin are shown. In the first experiment, cells were cultured for 
3 or 4 days after transduction and analyzed by FACS. We found a significant increase in 
the percent of S/G2/M cells in the Rheb2 GFP+ fraction compared to Mieg3 GFP+ cells at 
day 3 but not day 4 cultures, suggesting that this difference was detectable at early but 
not late culture time points. This significant increase was also found in day 3 cultures 
containing rapamycin, confirming increased cycling due to Rheb2 overexpression. The 
percent of Rheb2 GFP+ S/G2/M cells was decreased due to rapamycin treatment; 
however, this difference was not significant. Similar to the results of KSL expansion 
discussed earlier (Figure 16), this suggests that either mTOR is partially responsible for 
this increased cycling or that the intricacies of the mTOR signaling pathway confound 
this analysis. It is also possible that rapamycin inhibits the movement of cells out of 
S/G2/M by a checkpoint block; however, this is not likely given evidence that rapamycin 
blocks the transition from G1 to S in the cell cycle (Dutcher 2004). In the second 
experiment, Hoechst staining was performed at 4 and 5 days culture after transduction. 
The percent of cycling S/G2/M Rheb2 GFP+ cells was increased at both time points 
compared to Mieg3 GFP+ cells, although these were not significant. Interestingly, when 
comparing the GFP+ transduced population to the GFP- population within Rheb2 
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cultures, the percent of cycling S/G2/M GFP+ cells was significantly greater. This 
difference was found in cultures without and with rapamycin at both day 4 and day 5 
(Figure 18). Again, these results suggest that Rheb2 can increase the entrance of KSL 
cells into S/G2/M causing expansion of this population.  
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Figure 17: Effect of Rheb2 on KSL cycling in vitro. Transduced mouse BM MNCs 
were culture for 3 or 4 days (experiment 1) or 4 or 5 days (experiment 2) and stained for 
KSL markers as well as Hoechst DNA staining. Above are representative FACS plots 
from Day 3 cultures without rapamycin in experiment 1, illustrating that a higher 
percentage of GFP+ KSL cells in the Rheb2 GFP+ cultures fall within the S/G2/M region 
of Hoechst staining (right side of figure). The KSL gating parameters used were the 
same as those used in Figure 16. The Hoechst profile in GFP- populations was similar 
between Mieg3 and Rheb2 cultures (left side of figure). Tabulated data from both 
experiments is shown in Figure 18.  
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Figure 18: Effect of Rheb2 on KSL cycling in vitro. The percent of cycling KSL cells 
was measured by Hoechst staining. Two independent experiments are shown (mean ± 
SD). In experiment 1, cells were stained after 3 or 4 days in culture. In experiment 2, 
cells were stained after 4 or 5 days in culture. * indicates p<0.05 compared to Mieg3 
GFP+ cells, while † indicates p<0.05 compared to the Rheb2 GFP- fraction within the 
same sample.  
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Overexpression of Rheb2 impairs in vivo competitive repopulation of total transduced 
cells, while expanding immature hematopoietic cells in a short-term model 
To determine the effect of Rheb2 overexpression on mouse HSC functions such as 
differentiation and self-renewal, we performed in vivo competitive repopulation assays. 
As described in Materials and Methods, we transduced donor MNCs from C57/Bl6 mice 
(CD45.2+). These cells were mixed at a 1:1 ratio with competitor BM cells from BoyJ 
mice (CD45.1+) and were transplanted into heterozygous C57/Bl6-BoyJ 
CD45.1+/CD45.2+ recipient mice conditioned with 950 Rad of total body irradiation. To 
determine chimerism of donor cells, we isolated both PB and BM at 1, 2 and 4 weeks 
after transplantation and stained the cells with anti-CD45.1 and anti-CD45.2 antibodies. 
In addition, we stained the BM samples with c-kit, sca-1 and lineage antibodies to 
determine GFP+ cell numbers within immature populations of hematopoietic cells.  
Representative FACS plots are shown in Figure 19, demonstrating that donor 
(CD45.2+45.1-), competitor (CD45.1+45.2-) and recipient (CD45.1+45.2+) cells, as well as 
GFP+ and GFP- cells within the donor population can easily be detected in transplanted 
animal PB samples using FACS. Figure 20A shows the tabulated PB chimerism of donor 
transduced cells at 1, 2 and 4 weeks after transplantation. At 2 and 4 weeks, Rheb2 
transduced GFP+ cells had significantly impaired PB chimerism compared to Mieg3 
GFP+ cells (Figure 20A). At four weeks, the percent of CD45.2+GFP+ PB cells in animals 
transplanted with Rheb2 transduced cells was decreased 2-fold compared to the same 
population in animals transplanted with Mieg3 transduced cells. Importantly, the 
engraftment of CD45.2+GFP- cells was not significantly different between animals 
transplanted with Mieg3 or Rheb2 cells, suggesting a specific effect on the GFP+ fraction 
and confirming that transplanted cell numbers were equal between these groups. 
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In addition to PB, we determined the effect of Rheb2 overexpression on BM cell 
engraftment at 1, 2 and 4 weeks after transplantation. The engraftment of total donor 
CD45.2+ GFP+ cells is shown in Figure 20B, where we observed a similar trend as in PB 
samples. Animals transplanted with Rheb2 cells had significantly lower donor GFP+ cell 
engraftment compared to animals transplanted with Mieg3 cells at 2 and 4 weeks after 
transplantation. In the BM the impairment of engraftment due to Rheb2 was more 
dramatic than PB, with a greater than 5-fold reduction in total CD45.2+GFP+ in animals 
transplanted with Rheb2 cells compared to Mieg3 cells at four weeks.   
These results suggest that Rheb2 overexpression significantly impairs the ability of 
transduced cells to engraft recipient mice in an in vivo competitive repopulation model. 
This effect occurred shortly after transplantation, detected at two weeks after injecting 
the cells.  
To further elucidate the effect of Rheb2 overexpression in vivo, we determined absolute 
numbers of GFP+sca-1+lineage- (GFP+LS) cells in transplanted animals at 1, 2 and 4 
weeks after transplantation. The LS population was analyzed instead of KSL for two 
reasons. First, cell numbers in these animals were very low, especially at 1 week after 
transplantation, and second, the expression of c-kit was dim at 1 week after 
transplantation. The LS phenotype still defines an immature population of hematopoietic 
stem and progenitor cells. Figure 21A shows representative FACS plots of animals 
transplanted with Mieg3 or Rheb2 cells at 2 weeks after transplantation. Similar to our in 
vitro KSL expansion data, these plots show an increased percentage of GFP+LS cells in 
animals transplanted with Rheb2 cells. We determined the average absolute numbers of 
GFP+LS cells per mouse and show these results in Figure 21B. At 2 weeks after 
transplantation, animals transplanted with Rheb2 cells had significantly greater numbers 
of GFP+LS cells (19,457 ± 2250 GFP+LS cells in animals transplanted with Mieg3 cells 
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versus 31,132 ± 4340 GFP+LS cells in animals transplanted with Rheb2 cells, Mean ± 
SEM). This was a dramatic increase considering the impairment of overall donor GFP+ 
cells found in these animals at this time point. At 1 week post transplantation, numbers 
of Mieg3 and Rheb2 GFP+ LS cells were similar in recipient animals, suggesting that the 
increase observed at 2 weeks after transplantation was not due to early differences in 
homing of these cells. At 4 weeks post-transplantation, the numbers of GFP+LS cells in 
animals transplanted with Rheb2 cells were lower compared to Mieg3 cells, suggesting a 
transient effect of Rheb2 on the LS population.  
The data from these experiments suggest that Rheb2 expands immature hematopoietic 
cells in vivo, transiently increasing the absolute number of these cells, but causing a 
significant impairment in total cell engraftment, suggesting an ability of Rheb2 
overexpression to interfere with the normal repopulating ability or differentiation of these 
cells. 
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Figure 19: Donor, competitor and recipient cells are easily distinguished in 
competitive repopulation recipients. Representative FACS plots are shown for a 
recipient C57/BoyJ mouse transplanted with either Mieg3 or Rheb2-Mieg3 transduced 
cells. This illustrates that donor (CD45.2+45.1-), competitor (CD45.1+45.2-) and resident 
recipient (CD45.2+45.1+) cells were discriminated (left side of the figure). In addition, 
GFP+ cells within the donor population were identified in these recipients (right side of 
figure). Percentages are shown next to the FACS plots. The fluorochromes used for 
these analyses were CD45.1-PE and CD45.2-APC. 
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Figure 20: Effect of Rheb2 overexpression on in vivo short-term competitive 
repopulation. Transduced, unsorted mBM MNCs from C57/Bl6 animals were mixed 
with competitor BM cells from BoyJ animals and transplanted into irradiated 
C57/Bl6:BoyJ recipients. PB and BM were harvested at 1,2 and 4 weeks after 
transplantation. (A) The chimerism of transduced cells in the PB of recipient animals. (B) 
The chimerism of absolute numbers of transduced GFP+ donor cells in the BM of 
recipients. At least 5 in each group at each time point (mean ± SEM). 
 * p<0.05; ** p<0.01. 
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Figure 21: Effect of Rheb2 overexpression on engraftment of immature LS cells in 
vivo. (A) Representative FACS plots showing the percentage of GFP+ cells within the 
immature LS population in recipient animals at two weeks after transplantation. (B) 
Graph shows the absolute numbers of GFP+LS cells in the BM of recipients (at least 5 
recipients in each group at each time point, mean ± SEM). * p<0.05. NS = Not-
significant. 
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Rheb2 overexpression did not impair short-term 24 hour homing of transplanted cells 
Engraftment is a complex process involving many physiological processes. The ability of 
transplanted cells to move from the PB to the BM shortly after transplantation is called 
homing and is crucial for establishing stable engraftment of donor cells. To determine if 
the impaired engraftment of Rheb2 overexpressing cells was due to decreased homing 
of the cells, we transplanted transduced donor C57/Bl6 CD45.2 cells into irradiated 
recipient BoyJ CD45.1 mice without competitor cells and analyzed the BM of the 
recipient animals 24 hours after transplantation by FACS for chimerism of donor cells. 
Figure 22 shows representative FACS plots from recipient animals in A and tabulated 
total numbers of donor CD45.2+GFP+ cells in the graph in B. These results show that 
Rheb2 overexpression did not significantly impair the ability of the total transduced cell 
population to home to the BM, suggesting that the impaired engraftment is likely due to 
some other mechanism than homing. It should be noted that we did not determine the 
homing of immature cell populations such as lin-sca-1+ in this experiment, and these 
rarer populations could have been affected by Rheb2 overexpression without affecting 
the homing of the total GFP+ population. 
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Figure 22: Effect of Rheb2 overexpression on short-term homing in vivo. 1x106 
transduced, unsorted C57 BM MNCs were transplanted into irradiated BoyJ recipients. 
(A) Representative FACS plots gated on the donor (CD45.2+) population showing the 
percentage of GFP+ cells. (B) Graph shows total number of GFP+ donor cells per 
recipient (3 animals in each group). NS = not significant. 
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Overexpression of Rheb2 impaired long-term competitive repopulation of transduced 
cells 
We found that overexpression of Rheb2 expanded immature cells in vitro and in vivo 
while impairing the engraftment of total transduced cells, suggesting Rheb2 could impair 
the long-term engraftment ability of HSCs. To examine this, we performed additional 
competitive repopulation assays and followed donor cell engraftment for longer periods 
of time. These long-term engraftment experiments test the ability of HSCs to maintain 
repopulation of recipient animals, and are considered gold-standard assays for HSC 
self-renewal. We transduced donor cells from C57/Bl6 CD45.2+ mice and mixed with 
competitor cells from BoyJ CD45.1+ mice at two ratios, 1:1 and 0.4:1 donor to 
competitor, and transplanted the mixed cells into irradiated BoyJ CD45.1 recipient 
animals. PB chimerism of donor GFP+ cells was followed periodically by FACS staining 
for CD45.1 and CD45.2 markers. In addition, we determined the multilineage 
differentiation of Mieg3 and Rheb2 GFP+ cells by staining PB samples at 1 month post-
transplantation for lymphoid and myeloid cell markers.  
Figure 23 shows the results of PB chimerism from competitive repopulation assays using 
a 1:1 ratio of donor to competitor cells. Beginning at 1 month after transplantation and 
continuing through 5 months after transplantation, the percent of Rheb2 CD45.2+GFP+ 
cells out of total PB was significantly, at least 2-fold, lower than Mieg3 CD45.2+GFP+ 
cells. The percent of CD45.2+GFP- cells was similar between both groups of recipients, 
suggesting a specific effect on the transduced fraction and indicating that similar 
numbers of cells were transplanted into both groups of recipients. Although numbers of 
Rheb2 CD45.2+GFP+ cells were lower at all time points, the percent was stable from 
month to month and did not decrease further as the experiment continued, indicating 
that long-term repopulating cells were indeed present in the Rheb2 GFP+ fraction, but at 
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significantly lower numbers. Furthermore, it suggests that changes occurring shortly 
after transplantation were sufficient to cause impairment of the engraftment of long-term 
HSCs, a point discussed later in this thesis. 
Figure 24 shows PB chimerism from recipient animals transplanted with 0.4:1 donor to 
competitor cells. The same trend found in the 1:1 group was observed in these 
experiments with significantly lower numbers of Rheb2 CD45.2+GFP+ cells compared to 
Mieg3 CD45.2+GFP+ cells found in recipient animals at all time points after 
transplantation. Again, the engraftment of these cells was stable during the course of the 
experiment, suggesting that long-term engrafting HSCs were present in Rheb2 cells, 
albeit at lower numbers than Mieg3 cells. 
Rheb2 overexpression impaired secondary repopulation of transduced hematopoietic 
cells 
We have shown that animals transplanted with Rheb2 transduced cells had fewer 
numbers of GFP+ cells from one month through 5 months after transplantation. These 
data suggested that the numbers of long-term HSCs were decreased due to Rheb2. To 
determine the effect of Rheb2 overexpression on the self-renewal capacity of transduced 
HSCs in these primary recipients, we performed secondary transplantation. We isolated 
BM from primary transplant recipients 5 months after transplantation and transplanted 
these cells into irradiated BoyJ CD45.1+ recipients. We followed the chimerism in the PB 
of the animals periodically. Figure 25 shows BM chimerism in primary recipients at 5 
months after transplantation (Figure 25A) as well as the PB chimerism of secondary 
transplanted animals up to 2 months after transplantation (Figure 25B). Similar to 
primary transplant recipients, secondary recipients transplanted with Rheb2 transduced 
cells had a significantly lower percent of GFP+ cells in the PB compared to Mieg3 
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transduced cells. It is important to note that in the secondary transplant recipients, but 
not in primary recipients, the percentage of donor cells which are GFP- was slightly 
increased in animals transplanted with Rheb2 compared to Mieg3 transduced cells  
(28.0 ± 5.4% in animals transplanted with Mieg3 cells versus 36.5 ± 5.1% in animals 
transplanted with Rheb2 cells, Mean ± SEM). Importantly, this increase is not significant. 
A possible explanation for these results is that GFP expression is preferentially silenced 
in cells overexpressing Rheb2. This is not supported by our data from primary transplant 
recipients showing that the percentage of donor GFP- cells was similar in animals 
transplanted with either Mieg3 or Rheb2 transduced cells (see Figures 23 and 24). 
Future experiments using real-time PCR detection of proviral DNA in GFP- and GFP+ cell 
populations will rule-out a GFP silencing effect. Overall, our data support the conclusion 
that Rheb2 overexpression decreases numbers of long-term HSCs capable of 
repopulating secondary recipients.  
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Figure 23: Effect of Rheb2 overexpression on long-term engraftment in vivo. 
Transduced, unsorted mBM MNCs were mixed with BM cells from BoyJ animals at a 1:1 
donor to competitor cell ratio and transplanted into irradiated BoyJ recipients. PB was 
monitored in these animals at 1, 2.5, 3.5 and 5 months after transplantation. Two 
experiments combined, at least 11 animals in each group (Mean ± SEM).  
* p<0.05; ** p<0.02. 
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Figure 24: Effect of Rheb2 overexpression on long-term engraftment of 
transduced cells in vivo. Transduced, unsorted mBM MNCs were mixed with BM cells 
from BoyJ animals at a 0.4:1 donor to competitor cell ratio and transplanted into 
irradiated BoyJ recipients. PB was monitored in these animals at 1, 2.5, 3.5 and 5 
months after transplantation. Two experiments combined, at least 11 animals in each 
group (Mean ± SEM). ** p<0.02 
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Figure 25: Effect of Rheb2 overexpression on engraftment of secondary transplant 
recipients in vivo. Part A shows primary recipient BM chimerism in 1:1 group 5 months 
after transplantation (6 Mieg3 and 5 Rheb2 primary animals, Mean ± SEM). Part B 
shows PB chimerism in secondary animals transplanted with BM cells (2x106 each) from 
part A (total of 20 animals per group, Mean ± SEM). Note: 4 secondary animals 
transplanted from one Mieg3 primary animal died prematurely and were excluded from 
analysis of secondary transplant recipients. * p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
Rheb2 overexpression did not affect multilineage differentiation as measured by 
phenotypic surface markers 
To determine if both Mieg3 and Rheb2 transduced cells, once transplanted into recipient 
mice, exhibited multilineage differentiation, we analyzed the PB of 1:1 competitive 
transplant recipients (from Figure 23) by FACS at 1 month after transplantation for the 
surface molecules CD11b, CD3, Gr1 (L6-G) and B220. CD11b and Gr1 (L6-G) are 
myeloid markers, specifically monocyte and neutrophil markers. CD3 is a pan T-cell 
marker, and B220 is a B-cell marker. Therefore, this combination of surface markers 
determined if multilineage differentiation occurred in recipient mice. In Figure 26, we 
present FACS plots from representative Mieg3 and Rheb2 recipient animals showing 
that both the GFP- and GFP+ cell fractions exhibited multilineage surface molecule 
staining. Table 3 shows combined data from Mieg3 and Rheb2 animals showing the 
percentages within GFP- and GFP+ fractions of CD11b+, CD3+, GR1 (L6-G)+ and B220+ 
cells. Importantly, there were no significant differences in these percentages in Rheb2 
GFP+ cells compared to Rheb2 GFP- cells nor compared to Mieg3 GFP+ cells, indicating 
that overexpression of Rheb2 did not dramatically skew the transduced cells towards 
one lineage at the expense of another or block differentiation towards certain lineages.  
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Figure 26: Rheb2 transduced cells exhibited multilineage differentiation in vivo. 
Figure shows FACS plots of PB cells from representative animals transplanted with 
Mieg3 and Rheb2 transduced cells from the 1:1 competitive repopulation group shown in 
Figure 21 at 1 month after transplantation. Both Mieg3 and Rheb2 GFP+ populations 
expressed myeloid (CD11b and GR-1) and lymphoid (B220 and CD3) surface antigens, 
indicating multilineage differentiation. Tabulated data from 3 recipients in each group is 
shown in Table 3. 
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Mean ± S.D. % CD11b % CD3 % GR1 % B220
Mieg3 GFP- 50.9 ± 2.6 25.1 ± 0.7 32 ± 3.6 24.7 ± 4.4
Mieg3 GFP+ 47.8 ± 8.8 29 ± 6 30.6 ± 2.9 36.1 ± 1.4
Rheb2 GFP- 60.9 ± 15.9 19.9 ± 5.6 43 ± 13.7 18.7 ± 10.2
Rheb2 GFP+ 49 ± 31 30.5 ± 26 40.6 ± 23.4 27.9 ± 10.9
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Table 3: Rheb2 overexpression did not affect multilineage differentiation of 
transduced cells in vivo. Table shows combined data from 3 Mieg3 and 3 Rheb2-
Mieg3 transplant recipients. No significant differences were found between Mieg3 and 
Rheb2 GFP+ cells.  
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DISCUSSION 
Inhibition of CD26 peptidase activity: a strategy to increase hematopoietic cell 
engraftment 
The CD34+ fraction of hUCB contains HSCs capable of engrafting NOD/SCID mice in 
vivo. Our results demonstrated that inhibition of CD26 peptidase activity by pretreatment 
of donor CD34+ cells with 5 mM Diprotin A increased their in vivo engraftment in 
NOD/SCID mice, without affecting differentiation of the cells. In our experience, this 
enhancement was apparent when engraftment of control CD34+ cells was low. 
Additionally, the engrafting capability of NOD/SCID mice transplanted with CD34+ cells 
varied greatly between experiments. In one experiment, not shown, the engraftment of 
both control and Diprotin A-treated cells was greater than 55% and not significantly 
different when 1.8x105 CD34+ cells were injected. In another experiment we noted no 
detectable engraftment with injection of a similar number (1.8x105) of CD34+ cells, with 
or without Diprotin A pretreatment. As shown in Figure 5, we did not detect a dose-
response in engraftment of varying cell numbers, but the Diprotin A pretreated group 
was enhanced in engraftment at each of these different cell infusion numbers, and this 
enhancement was significant after pooling the animals into two groups. Thus, 
enhancement of engraftment with Diprotin A related more to levels of control cell 
engraftment, so long as these levels were detectable, than to the numbers of cells 
transplanted into the recipients.  
Our present study, in light of previous work (Tian et al. 2006; Peranteau et al. 2006; 
Christopherson et al. 2004) on mouse to mouse transplantation, strongly suggests that 
CD26 activity plays an important role in hematopoietic cell engraftment. A practical 
strength of these studies is the ability to enhance transplantation by a simple 15 minute 
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pretreatment of cells to diminish CD26 activity (Christopherson et al. 2004). This 
treatment requires very little ex vivo manipulation of donor cells. While this study 
demonstrates the positive effects of treating just the donor cells, it is possible that 
treatment of both donor cells and recipients may have greater effects on enhancing 
transplantation, especially given the fact that CD26 is expressed in many different tissue 
beds within the body (Pro and Dang 2004; Demuth et al. 2005). Our group has shown 
that in vivo treatment of recipient mice with Diprotin A enhanced the primary competitive 
and secondary non-competitive repopulating capacity of untreated congenic mouse 
bone marrow donor HSCs (Broxmeyer et al. 2007). However, an advantage of treating 
donor cells alone is that it would avoid possible side effects of potential total body CD26-
inhibition of recipients, even though CD26 inhibitors are reversible. 
It was important to determine whether CD26 was expressed on phenotypically defined 
subsets of human HSCs. Since we found preferential expression of CD26 on more 
immature cells within the CD34+ population, this suggests that strategies to eliminate 
CD26 activity by depletion of CD26+ cells could potentially have a negative impact on 
transplantation outcomes, since this might eliminate HSCs. Thus, strategies to inhibit 
CD26 peptidase activity, rather than remove CD26-expressing cells, may be more 
appropriate for clinical use.  
The exact mechanism explaining the in vivo effects we and other laboratories have 
observed due to inhibition of CD26 has not been fully elucidated. There is ample 
evidence suggesting that CD26 is acting through its ability to cleave SDF-1/CXCL12 to 
an inactive form, thus negatively affecting the homing and engraftment of HSCs in vivo. 
First, we know that CD26 acts in vitro to cleave SDF-1/CXCL12 and that this form 
negatively affects the chemotaxis. Second, it is likely that the peptidase activity of CD26 
is responsible for these observations, since Diprotin A acts by competitively inhibiting 
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this property of the enzyme (Rahfeld et al. 1991). Third, the increased short-term homing 
observed by our laboratory in mouse congenic transplants using Diprotin A pre-treated 
or CD26-/- cells was reversed by treatment with AMD3100, a selective CXCR4 
antagonist, suggesting that the effects are mediated through the SDF-1:CXCR4 axis 
(Christopherson et al. 2004). Figure 27 shows a diagram of the proposed mechanism of 
action of CD26 in vivo based on evidence to this point and emphasizing its effect on 
SDF-1/CXCL12. It is likely that multiple mechanisms account for the effect of CD26 
inhibition. Multiple cell populations express CD26, including HSCs, accessory donor 
cells and recipient stromal cells. Under conditions where CD26 peptidase is active, SDF-
1 is cleaved to an inactive, antagonist form capable of inhibiting migration of HSCs into 
the BM stroma. After Diprotin A treatment of any of the CD26+ cell populations, SDF-1 is 
preserved in its full-length active form and stimulates migration of HSCs into the BM 
stroma (Figure 27). However, there are likely additional processes occurring which 
account for some of the mechanism. First, we have summarized here the wide effect 
CD26 has on many different chemokines. It is possible that in vivo CD26 could be 
cleaving other chemokines, in addition to SDF-1/CXCL12, that affect the homing of 
HSCs and/or accessory cells leading to effects on establishment of the hematopoietic 
niche. Furthermore, in addition to its well-established peptidase activity, CD26 has been 
shown to bind to components of the extracellular matrix (ECM) as well as interact with 
cell-surface signaling proteins, including fibronectin, collagen, adenosine deaminase 
(ADA) and CD45 (Pro and Dang 2004; De Meester et al. 1999). The physiological 
relevance of these interactions is not well known, but they illustrate the point that CD26 
is more than a simple dipeptidase enzyme. There is some signaling associated with 
CD26 as well, as studies using cross-linking anti-CD26 antibodies have shown multiple 
tyrosine phosphorylation events occur downstream (De Meester et al. 1999). This is 
probably not a direct effect of CD26, since the cytoplasmic region is very short, and is 
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likely mediated by a CD26 binding partner. Inhibiting the peptidase activity of CD26, 
although unlikely, could conceivably have an effect on any or all of these non-enzymatic 
functions and could be part of the CD26 mechanism of action in vivo. Finally, there is 
evidence that CD26 can functionally bind to CXCR4, and this CD26:CXCR4 complex 
can be internalized by SDF-1/CXCL12 stimulation of lymphocytes (Herrera et al. 2001). 
This internalization, if occurring in a fraction of the CXCR4 pool, could have an 
amplifying effect on CD26 inhibition by decreasing CD26 expression on the cell surface. 
Whether this interaction is modulated by cleaved or full-length SDF-1 and whether this 
interaction is affected by inhibition of CD26 peptidase activity is an interesting avenue of 
further study.   
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Figure 27: Proposed mechanism of CD26/DPPIV action in vivo. Transplanted HSCs 
migrate into the recipient BM due to various mechanisms, one of which is SDF-
1/CXCL12 signaling. CD26 molecules, expressed on donor HSCs, donor accessory cells 
(non-HSCs) and recipient BM cells are proposed to cleave SDF-1/CXCL12 in vivo to an 
inactive, truncated form which negatively affects the engraftment of the donor HSCs. In 
the presence of CD26 inhibitors such as Diprotin A, this cleavage of SDF-1 is blocked 
and the HSCs are enhanced in migration into and retention within the BM.   
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Studies by two independent laboratories published at the same time as our own 
confirmed the effect of inhibition of CD26 on engraftment of human HSCs 
(Christopherson II et al. 2007; Kawai et al. 2007). The first, published by Christopherson 
et al  (Christopherson II et al. 2007) showed that pre-treatment of either CD34+-purified 
or lineage-depleted human CB cells with Diprotin A resulted in enhanced engraftment of 
NOD/SCIDβ2mnull mice. The NOD/SCIDβ2mnull model is an improvement of the 
NOD/SCID strain by deletion of the β2-microglobulin gene, leading to fewer natural killer 
(NK) cells and better engraftment of the human cells (Christianson et al. 1997; Kollet et 
al. 2000). The effect of Diprotin A in this study was more dramatic on the lineage-
negative CB population, which had 7.5 fold increased engraftment compared to a 4 fold 
increase in highly purified CD34+ cell treated with Diprotin A. The percent of CD26+ cells 
was higher in the lineage-negative population compared to the CD34+ population as was 
the CD26 activity, while only about 30% of the lineage-negative population was CD34+. 
This suggests that CD34-CD26+ accessory cells  negatively affect engraftment of the 
repopulating HSCs and that inhibiting these cells as well as the CD34+CD26+ cells leads 
to dramatic increases in cell engraftment.  The second study on human HSCs and CD26 
was published by Kawai et al (Kawai et al. 2007) and showed that in vivo treatment of 
NOD/SCID animals with Diprotin A significantly enhanced the engraftment of G-CSF 
mobilized peripheral blood (MPB) CD34+ cells. In addition, this treatment enhanced the 
engraftment of retrovirally transduced human CD34+ MPB cells. This enhancement of 
engraftment was found only when Diprotin A was injected into the animals at the same 
time as injection of CD34+ cells, suggesting that CD26-inhibition of the recipient mouse 
cells may be more important than pre-treatment of the donor cells. This lack of pre-
treatment effect of Diprotin A was found despite the fact that the cells expressed CD26 
and exhibited CD26 activity after an ex vivo culture period. The discrepancy in this study 
could reflect a difference between the HSCs derived from G-CSF MPB and those from 
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CB used in ours (Campbell et al. 2007a) and Christopherson’s (Christopherson II et al. 
2007) studies. Additionally, it illustrates the probable role of the recipient BM stroma in 
affecting engraftment of donor cells through CD26 mechanisms.  
The potential clinical use of this strategy will undoubtedly require more work with animal 
models, such as canine and primate, using CB as well as other transplantable sources 
such as MPB and BM. As stated above, it will be important to determine whether treating 
the donor cells or recipient is more effective at enhancing engraftment. For MPB donor 
cells, treatment of the cells alone was not effective at increasing engraftment, but for CB 
donor cells this pre-treatment did enhance engraftment. It may be that a combination of 
treating the cells and the recipients is best given the fact that CD26 is expressed in 
many tissue beds and found in a soluble form in the plasma (Pro and Dang 2004).  
CD26 plays a role in other biological processes. Much work has been done on the 
relationship between CD26, glucose metabolism and Type 2 diabetes. CD26 inhibitors 
are currently in clinical use for the treatment of diabetes. CD26 can cleave hormones 
such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide 
(GIP), both of which can stimulate insulin release in the post-prandial response to foods 
(Deacon and Holst 2006; Demuth et al. 2005). CD26 cleavage of these hormones has a 
negative effect on glucose metabolism, and inactivation of CD26 activity is thought to 
extend their half-life leading to better blood glucose responses in diabetics. The fact that 
CD26 plays an important role in glucose metabolism led various companies to develop 
multiple CD26 inhibitors, with a least one, Sitagliptin (Merck) having FDA approval 
(Nathan 2007). These compounds vary in their structures, mechanism of action 
(competitive vs. non-competitive), and duration (long-lasting vs. short-lasting). The ability 
of these newer, clinical grade CD26 inhibitors to affect HSC biology should be tested, 
first in animal models, to determine if they can work in these contexts. The results of 
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clinical trials on diabetes to date have shown minimal toxicity due to these compounds 
(Deacon and Holst 2006). However, it is important to note that long-term follow up has 
not taken place and firm conclusions about the safety of these inhibitors cannot be made 
at this time. In addition, there are safety factors to consider in transplant patients who 
are immunosuppressed and have hematologic pathologies; the fact that these drugs are 
safe in one population does not guarantee that they will be safe in another. There is also 
a concern that inhibiting CD26 in a human transplant recipient could lead to HSCs 
seeding other tissue beds, besides BM, in the body that produce SDF-1/CXCL12 
gradients (e.g. lung and lymphoid organs), a phenomenon known to occur with BM cells 
(Dooner et al. 2004). Whether the HSCs in these non-BM environments could thrive, 
proliferate and possibly harm the patient may be unlikely but is still a concern.  
It is our goal that the ability to increase engraftment due to inhibition of CD26 activity will 
be able, alone or combined with other strategies such as ex vivo expansion and 
immunotherapy, to extend the potential therapeutic uses of limiting hematopoietic cell 
populations, such as those from human CB. This therapy may provide more patients 
with the best chance of a successful outcome after hematopoietic cell transplantation. 
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The novel ras molecule Rheb2: diverse roles in expansion and repopulation of 
hematopoietic cells 
The second part of our study involved the role of Rheb2 in affecting hematopoietic cell 
functions, especially in vivo engraftment. We studied Rheb2 mainly because of its role in 
mTOR signaling. Studying the role of intracellular signaling proteins, including members 
of the ras family, is important for determining how HSC functions such as self-renewal 
and differentiation are regulated. Understanding these processes is important for clinical 
expansion of HSCs, transduction and other therapies.  
We report here that overexpression of Rheb2 leads to increased mTOR signaling in two 
mouse hematopoietic cell lines, 32D and BaF3. Although Rheb2-mTOR signaling has 
been demonstrated in other cell types, no researchers have studied the signaling of this 
molecule in hematopoietic cells. In addition to activating mTOR signaling, we found that 
Rheb2 overexpression enhanced proliferation of 32D and BaF3 cells in response to 
delayed IL-3 addition, suggesting that Rheb2 plays a role in IL-3 mediated survival 
and/or proliferation. In fact, the importance of mTOR in mediating IL-3 effects has been 
previously reported (Cruz et al. 2005).  
We found that overexpression of Rheb2 enhanced the in vitro growth and survival of 
primary mouse hematopoietic cells, including the progenitor cell subsets. Total 
proliferation of transduced FACS sorted GFP+ mouse BM MNCs was enhanced by 
Rheb2. In addition, the colony-forming ability of mouse hematopoietic progenitors and 
their expansion in liquid culture was enhanced by Rheb2 overexpression. These positive 
effects can be explained by a variety of mechanisms including enhancement of 
proliferation, differentiation or survival. Increased proliferation is supported by our data 
showing expansion of progenitors over time in liquid culture due to Rheb2 
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overexpression (Figure 13). In addition to proliferation, enhanced survival played an 
important role in Rheb2 effects, as demonstrated by increased colony-formation in 
delayed growth factor addition colony assays. Interestingly, we found that the pro-
survival chemokine SDF-1/CXCL12 could not further enhance the survival of Rheb2 
transduced cells. This suggests that SDF-1 and Rheb2 may stimulate the same 
signaling pathways leading to enhanced cell survival, or alternatively, that there is an 
upper limit to enhanced survival and Rheb2 overexpression may reach that limit. We 
showed that SDF-1 stimulation of mouse BM MNCs enhanced signaling through the 
mTOR pathway, suggesting that this pathway may be activated by both SDF-1 and 
Rheb2 leading to cell survival. To our knowledge, this is the first report of mTOR 
activation by SDF-1 stimulation. Further experiments need to be performed to fully 
elucidate the relationship between Rheb2, SDF-1 and mTOR, but our preliminary data 
suggest this could be an interesting avenue of study.  
Our final piece of in vitro data showed that Rheb2 overexpression expanded the percent 
of KSL cells in liquid cultures. Rheb2 had a substantial effect on this expansion, with a 
greater than 4-fold increase in KSL percentage 4 days after transduction. This expansion 
was specific for the GFP+ transduced cell fraction, and percent KSL cells was similar in 
the non-transduced GFP- fraction in both Mieg3 and Rheb2 cultures. These data 
suggest, along with the colony assays, that Rheb2 overexpression expands immature 
hematopoietic cells. It is important to point out that the KSL phenotype does not identify 
a pure population of mouse HSCs, and there exists the possibility that an immature 
progenitor cell population was expanded in the Rheb2 liquid cultures, as opposed to true 
multipotent HSCs. In the future, more combinations of surface markers, such as CD34 
and thy1.1 can be used to further delineate this expanded population. Alternatively, this 
population can be FACS sorted and transplanted in vivo to assess multipotentiality. 
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Treatment of these liquid cultured cells with 50 nM of rapamycin, a specific mTOR 
inhibitor, significantly decreased the percent of GFP+ KSL cells in Rheb2 cultures. The 
fact that rapamycin only partially reduced the percentage of Rheb2 GFP+ KSL cells, and 
these percentages were still enhanced compared to Mieg3 cultures, suggests that other 
signaling pathways may be involved in this expansion. Alternatively, this may suggest 
that our concentration of rapamycin was too low to completely reverse the Rheb2 
overexpression. In fact, this 50 nM concentration is lower than studies on 
megakaryocyte differentiation which used 100 nM rapamycin without significant cell 
death (Raslova et al. 2006). Additionally, rapamycin may need to be periodically 
replenished in these cultures in order to maintain stable levels of the compound, a 
change we will test in the future. Finally, mTOR signaling is complicated with various 
negative and positive feedback mechanisms regulating the signaling upstream of mTOR 
through the Akt pathway. Under conditions of Rheb2 overexpression, the interplay 
between these positive and negative feedback loops is likely altered, partly explaining 
why rapamycin treatment only partially reduced the expansion of KSL cells. Also, only 
one of the two mTOR complexes (mTORC1) is inhibited by rapamycin. The possible 
activity of Rheb2 on mTORC2, which is unaffected by rapamycin, could also explain the 
lack of reversal of KSL expansion due to rapamycin, especially given the fact that this 
complex can activate signaling through the Akt pathway (Wullschleger et al. 2006). As 
previously mentioned, Rheb1 does not have appreciable activity on mTORC2; however, 
no information is available on the activity of Rheb2 on this complex. 
Overall our in vitro data showed that Rheb2 overexpression positively regulates 
hematopoietic cell growth and survival. Furthermore, we provide evidence that 
phenotypic HSCs, identified as KSL cells, are expanded by Rheb2, a process at least 
partially mediated by mTORC1. The next question we addressed, using a variety of in 
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vivo assays, was whether this expansion of immature cells in vitro could translate into 
enhanced engraftment in vivo, a goal of any ex vivo expansion protocol. 
In contrast to the in vitro expansion data, Rheb2 overexpression significantly impaired 
the engraftment of transduced cells in both short-term and long-term competitive 
repopulation assays. In short-term studies, the engraftment of total GFP+ transduced 
cells was impaired at 2 and 4 weeks post-transplantation in both the PB and BM of 
recipient animals. However, similar to the in vitro expansion data, immature LS cells 
were transiently expanded at 2 weeks post-transplantation in recipient animals due to 
Rheb2 overexpression, suggesting that Rheb2 positively affected the proliferation of 
these cells after transplantation. This effect was short-lived and not found at 1 month 
post-transplantation. From 1 month on in long-term competitive transplant recipients, 
Rheb2 overexpression resulted in significantly decreased percentages of GFP+ donor 
transduced cells in the PB. This trend was found in animals transplanted with a 1:1 or 
0.4:1 ratio of donor to competitor cells. Additionally, the engraftment of donor Rheb2 
GFP+ cells was significantly lower in secondary transplant recipients, measuring the self-
renewal of long-term HSCs. Overall, the data on in vivo donor cell engraftment suggest 
that Rheb2 expands immature cells after transplantation resulting in depletion of their 
short and long-term repopulating ability. 
Interestingly, the level of donor GFP+ cells was stable in animals transplanted with 
Rheb2 cells from 1 month on in competitive assays, suggesting that long-term 
repopulating HSCs were indeed present in these animals, but at significantly lower 
numbers than animals transplanted with control Mieg3 cells. This suggests that Rheb2 
effects occur shortly after transduction and transplantation to deplete the numbers of 
HSCs. The cells that remain engrafted in these animals have likely either adapted to 
these adverse effects or have downmodulated the expression of Rheb2 in order to 
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maintain themselves. These are hypotheses we can test in future studies using real-time 
PCR or Western blotting to follow the expression of Rheb2 in vivo over time and the 
phosphorylation status of mTOR pathway effectors. 
At first glance, the in vivo data presented seem to conflict with out in vitro data. On the 
one hand, Rheb2 expanded phenotypic immature cells in vitro and in vivo. On the other 
hand, Rheb2 depleted the engraftment of functional repopulating HSCs in vivo. This 
begs the question of what mechanism explains the Rheb2 effect on repopulating ability 
(i.e. self-renewal) of mouse HSCs. More generally, it suggests a negative relationship 
between proliferation of immature hematopoietic cells and maintenance of their 
repopulating activity. Previous work (Cheng et al. 2000; Yilmaz et al. 2006) suggests 
that, in fact, this is often times the case and factors which expand HSCs by pushing 
them into a proliferative state have negative consequences on engraftment and 
repopulating ability. 
The Relationship between proliferation and maintenance of repopulating activity in HSC 
expansion 
For any ex vivo expansion approach to be clinically effective at treating patients, the 
expanded HSC population must be similar to fresh HSCs in their ability to maintain long-
term repopulation. A general problem with ex vivo HSC expansion is the impact of 
proliferation on the ability of HSCs to maintain long-term engraftment. The majority of 
long-term repopulating HSCs are found in a quiescent state in vivo under steady-state 
conditions (Bradford et al. 1997; Cheshier et al. 1999; Passegue et al. 2005; Orschell-
Traycoff et al. 2000), and the balance between quiescence and proliferation in vivo 
during hematopoietic repopulation is thought to be important for maintaining stable 
repopulation in transplant recipients. A significantly higher percentage of phenotypic LT-
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HSC in the G0 (quiescent) phase of the cell cycle are able to stably engraft recipient 
animals compared to cells in G1 or S-G2/M phases (Passegue et al. 2005), suggesting 
that specific molecular changes occurring as cells move through the cell cycle impact 
their homing and engrafting ability. This concept has been observed repeatedly in the 
past few years as researchers analyze genes responsible for controlling proliferation 
and/or cell cycle in HSCs.  
A well-known example of how proliferation impacts repopulating ability comes from a 
study of p21 knockout mice (Cheng et al. 2000). p21cip1/waf1 is a member of the family 
of cyclin dependent kinase inhibitors (CDKI) and specifically regulate the movement of 
cells out of G1 through the rest of the cell cycle (Cheng et al. 2000). Researchers 
discovered after knocking out p21 in mice that fewer BM cells were found in a quiescent 
G0 cell-cycle state, as measured by pyronin RNA staining. This increase in cycling of the 
BM cells correlated with an increased number of immature colony-forming cells under 
basal conditions using a cobblestone area forming assay, a surrogate in vitro assay for 
quantifying stem cells. However, HSC numbers were dramatically decreased in 
response to BM conditioning by 5-FU, which kills cycling BM cells and causes the stem 
cells to undergo stress in replenishing them. Furthermore, in transplant studies, p21 
knockout bone marrow cells were significantly impaired in their ability to maintain 
engraftment and survival in serially transplanted recipients, suggesting that p21 loss 
negatively affects the ability of HSCs to maintain self-renewal capacity and engraft 
recipient animals (Cheng et al. 2000).  
Further information on proliferation and repopulation has been found in studies on many 
different molecules, including the transcription factor Gfi1, the GTPase Cdc42, Wnt 
extracellular signaling molecules, and the phosphatase molecules Shp-2 and PTEN 
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(Zeng et al. 2004; Yang et al. 2007; Fleming et al. 2008; Chan et al. 2006; Yilmaz et al. 
2006; Zhang et al. 2006).  
Gfi is a nuclear transcription factor important in T cell proliferation and maturation and in 
interacting with signal transducing transcription factors such as STAT proteins (Rodel et 
al. 2000). Studies of the Gfi-/- knockout mouse revealed a role for this protein in 
restraining mouse HSC proliferation and maintenance of long-term repopulating activity 
(Zeng et al. 2004). Gfi-/- mice had reduced numbers of HSCs and HPCs in vivo under 
steady-state conditions, which were significantly impaired in their ability to repopulate 
transplanted recipient mice, were highly proliferative and not quiescent, suggesting that 
loss of this transcription factor puts HSCs into cell cycle and out of a quiescent state and 
leads to their exhaustion (Zeng et al. 2004). This mechanism of loss of repopulating 
ability may involve a p21 mediated mechanism as this molecule was downregulated in 
cells lacking Gfi (Zeng et al. 2004). A similar phenotype was discovered by researchers 
studying the knockout mouse model of the Rho GTPase protein Cdc42, a protein 
involved in cytoskeletal dynamics and adhesion (Yang et al. 2007; Etienne-Manneville 
and Hall 2002). Loss of Cdc42 led to HSC proliferation, less quiescent HSCs, expansion 
in vivo and impaired repopulation in transplant recipients (Yang et al. 2007). Contrary to 
the p21 and Gfi studies, the loss of Cdc42 dramatically impaired the ability of HSCs to 
home to and lodge within the BM of recipients, adhere and migrate in in vitro assays, 
and interact with the BM niche/stroma in vivo (Yang et al. 2007). Again, the loss of 
Cdc42 results in a decrease in p21 expression, suggesting a role for this protein in the 
mechanism (Yang et al. 2007).  
Stimulation of Frizzled receptors by Wnt proteins can lead to expansion of HSCs in vitro. 
The mechanism of this expansion, and the effect of Wnt proteins on HSC repopulating 
activity, had not been studied thoroughly until recently. A group using a transgenic 
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mouse expressing an inhibitor of Wnt signaling, Dickkopf1, restricted to osteoblast 
expression, found that decreased Wnt signaling in HSCs within in vivo BM niches 
decreased the percentage of quiescent HSCs and impaired their long-term repopulation 
in serially transplanted recipient mice (Fleming et al. 2008). This study suggests a role 
for Wnt signaling in maintaining HSC quiescence in vivo, preventing exhaustion of the 
repopulating activity.  
The phosphatases Shp-2 and PTEN play important roles in cell growth, differentiation 
and survival of hematopoietic and other tissues. Shp-2 is involved in modulating 
signaling via various growth factor receptor classes (Qu 2000), impacting the signaling 
from cytokines such as SCF, IL-3, M-CSF, GM-CSF and EPO (Chan et al. 2006). 
Decreased function of Shp-2 in haploinsufficient BM cells caused a decrease in the 
percentage of quiescent cells and dramatically decreased the long-term repopulating 
ability of the cells (Chan et al. 2006). Importantly, Shp2+/- cells were able to home to 
recipient BM normally compared to wild-type cells, suggesting that the engraftment 
defects were not due to a defective ability of the cells to reach the BM after 
transplantation (Chan et al. 2006). 
Phosphatase and tensin homologue (PTEN) is an important phosphatase involved in 
modulating the PI3K pathway by removing phosphate groups from inositol tri-phosphate, 
a second mediator in this pathway. PTEN mutations are found in many cancers, 
including leukemia (Cheong et al. 2003; Roman-Gomez et al. 2004; Aggerholm et al. 
2000; Dahia et al. 1999). PTEN knockout is embryonic lethal in the mouse, but recently 
a conditional knockout mouse was developed and analyzed for changes in the HSC 
compartment (Yilmaz et al. 2006; Zhang et al. 2006). Two independent groups found 
that loss of PTEN dramatically affected HSC growth and behavior (Yilmaz et al. 2006; 
Zhang et al. 2006). Loss of PTEN reduced the percentage of quiescent HSCs, which 
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was correlated with a transient, short-lived increase in the number of HSCs in vivo, 
followed by a decrease in these numbers, and a concomitant increase in these numbers 
in peripheral tissues, indicating an increased mobilization tendency in cells lacking PTEN 
(Zhang et al. 2006). In vivo repopulating ability of PTEN knockout BM cells was 
significantly impaired compared to wild-type mice (Yilmaz et al. 2006; Zhang et al. 2006). 
Short-term homing of PTEN deficient cells was unaffected (Zhang et al. 2006), 
suggesting that the HSCs are exhausted by the loss of PTEN, due to increased cycling 
and an inability to maintain quiescence. Both groups found that the loss of PTEN led to 
leukemia; however, the depletion/exhaustion of HSCs occurred in animals in which 
leukemia never developed, suggesting that this depletion is not secondary to BM 
crowding or other changes due to leukemic development (Yilmaz et al. 2006). 
Additionally, one of the two groups studying this PTEN conditional knockout found that 
inhibiting the mTOR pathway by treating the mice in vivo with rapamycin led to the 
resolution of leukemia and, importantly, the restoration of normal numbers of HSCs by 
preventing increased cycling and exhaustion. This study suggests that activation of 
mTOR, a downstream effector of PI3K signaling, is responsible for some of the effects 
seen due to loss of PTEN (Yilmaz et al. 2006). 
It is clear from the above discussion that various molecules have been studied regarding 
their ability to affect proliferation and maintenance of repopulating ability of HSCs. The 
goal of ex vivo expansion of HSCs is made more difficult by these studies showing a 
trade-off between proliferation and maintaining repopulating activity in HSCs.  
In the current study, we found similar data suggesting that Rheb2 pushes HSCs into 
cycle at the expense of their repopulating ability (Figures 17 and 18). We found that a 
higher percentage of Rheb2 GFP+ cells were in cycling S/G2/M status compared to 
Mieg3 and the GFP- fractions. This is one explanation for the loss of repopulating ability 
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when Rheb2 is overexpressed in immature hematopoietic cells. Under these 
circumstances, similar to the PTEN or p21 knockout models, the transduced HSCs may 
lose their ability to maintain the balance between proliferation and self-
renewal/repopulating ability, leading to their exhaustion in vivo.  
Other mechanisms could be involved in the phenotype observed due to Rheb2 
overexpression, including possible effects on differentiation and survival. No defect in 
differentiation was observed at 1 month after competitive transplantation. However, 
earlier time points after transplantation were not measured and it is possible that a 
transient effect on differentiation, similar to the effect on LS expansion, could be present 
in these recipient mice. It is less likely that Rheb2 is preventing differentiation of 
progenitor cells, since we found increased colony numbers in methylcellulose colony 
assays. It is possible that Rheb2 can enhance differentiation, resulting in more colonies 
in the methylcellulose assays and depletion of HSCs in vivo. There also exists the 
possibility that Rheb2 overexpression negatively affects survival of HSCs. However, in 
progenitor cells, Rheb2 enhanced survival in delayed growth factor methylcellulose 
assays. We did not determine levels of apoptosis in more immature HSC populations.  
Hematopoietic cell transplantation (HCT) is a complex process which has progressed 
dramatically in the past 20 years but still has limitations. In this study, two different 
approaches hypothesized as important in hematopoietic cell engraftment have been 
evaluated: modulation of engraftment by factors affecting homing and modulation of 
engraftment by signaling molecules involved in hematopoietic cell proliferation. First, 
expanding on studies using mouse to mouse transplantation, we found that inhibition of 
the peptidase CD26/DPPIV enhances engraftment of hUCB CD34+ cells in a xenograph 
model. This provides a rationale for continuing study and determination of whether this 
strategy will have a positive effect in human hematopoietic transplantation, especially 
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using human umbilical cord blood as a donor source. In the study on Rheb2 
overexpression, we found that Rheb2 could indeed expand hematopoietic progenitor 
and stem cells, but impaired the repopulating ability of the HSCs. Elucidating the 
downstream effectors responsible for these observations could help determine which 
molecular targets are responsible for maintaining the delicate balance between 
proliferation and repopulating activity and how manipulation of these pathways could be 
used clinically to enhance HCT. 
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FUTURE OBJECTIVES 
Testing FDA-approved CD26 inhibitors in animal models 
As stated in the Discussion, FDA CD26/DPPIV inhibitors are available for the treatment 
of type II diabetes. Our goal is to test these inhibitors in animal models of hematopoietic 
engraftment to determine if they can enhance this engraftment similar to Diprotin A. Our 
plans are to test these on the donor cells as well as recipient cells to determine which 
treatment or combination of treatments will be more effective at enhancing engraftment.  
CD26 expression on human HSCs and mechanism 
We found that a higher percentage of immature CD38-CD34+ cells expressed CD26 
compared to more mature CD38+CD34+ cells. This suggests a relationship between 
purity of HSCs and CD26/DPPIV expression, indicating part of the mechanism 
responsible for Diprotin A effects may be inhibition of CD26 on immature HSCs, 
enhancing their homing and engraftment. To test this hypothesis, we can FACS sort 
CD26+CD34+ and CD26-CD34+ and pretreat with Diprotin A before transplantation into 
NOD/SCID mice to test whether the CD26+ population contains a higher proportion of in 
vivo engrafting HSCs.  
To determine if the SDF-1-CXCR4 axis accounts for the effects due to CD26 expression, 
we can perform in vivo homing experiments using either CD34+ or Lineage-negative 
hUCB cells in the presence or absence of AMD3100 treatment. We would expect this 
treatment to block the Diprotin A enhanced engraftment.  
Rheb2 in vivo mechanisms 
We have provided evidence that Rheb2 enhances the cycling of immature hematopoietic 
populations in vitro, correlated with a transient increase in these numbers in vivo 
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followed by their exhaustion. We propose that the in vivo mechanism responsible for this 
exhaustion is similar to the in vitro increased cycling observed. Therefore, to test this, we 
will transplant recipient mice with Rheb2 transduced cells and follow the numbers of 
immature cells (as measured by Lin-Sca-1+) at least weekly after transplantation. At the 
same time, we will determine the cycling status of these cells in vivo using Hoechst 
33342 staining, and we will incorporate Pyronin Y staining to measure the percentage of 
cells in G0 versus G1 stages. Our hypothesis is that Rheb2 overexpression will increase 
the cycling of cells in vivo corresponding to their increased numbers, followed by a 
decrease in cycling and a decrease in the total numbers. 
Silencing of Rheb2 and effects on hematopoiesis 
As shown in Figure 9, we have developed an shRNA retroviral vector capable of 
knocking down the expression of Rheb2. Our future goals will be to silence Rheb2 in 
primary hematopoietic cells and use these in functional assays such as in vitro colony-
forming assays and in vivo competitive transplantations. We expect that Rheb2 knock-
down will decrease the colony-forming ability of the transduced cells in vitro. In vivo, we 
expect knock-down of Rheb2 may prevent exhaustion of HSCs leading to increased 
long-term numbers. However, if Rheb2 knock-down negatively affects survival, as may 
be expected, we may find a loss of HSCs in vivo due to cell death. In addition to knock-
down of Rheb2, we plan to study the level of expression of Rheb1 in hematopoietic cells 
and compare this to Rheb2 expression to understand better which protein is involved in 
mouse hematopoietic cell functions. 
Rheb2 effects on mTORC2 
Our in vitro experiments suggested that Rheb2 enhanced mTORC1 signaling in 
hematopoietic cell lines; however, rapamycin only partially decreased BM KSL 
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expansion in liquid cultures. First, we will test higher doses of rapamycin and replenish it 
frequently in these liquid cultures to determine if mTORC1 is involved to a greater extent 
than our current studies indicate. It is interesting to note that the role of Rheb2 on 
mTORC2 has not been published and may help to explain some of the effects we have 
observed. To test the relationship between Rheb2 and mTORC2, we will use Rheb2 
overexpressing and Rheb2 silenced cell lines to determine if downstream mTORC2 
targets are affected by Rheb2 modulation. One target of mTORC2 is AKT which is 
phosphorylated at Serine 473 by mTORC2 (Corradetti and Guan 2006). By Western 
blotting for these and other effectors of mTORC2, we can determine the role of Rheb2 in 
its modulation – a potentially novel finding. 
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